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The purpose of this project was to expand the understanding and utility of a pre-existing 
family of engineered amine dehydrogenases (AmDHs) which catalyze the reductive 
amination of prochiral ketones to chiral amines. Work toward this goal was focused in 
three generally independent directions, enzyme improvement through site-directed 
mutagenesis, understanding of the kinetic mechanism, and reaction engineering toward 
scalable continuous amine production. Through a combination of mutations shown to have 
positive effects in other related amine and amino acid dehydrogenases, new AmDH 
variants were produced with multiple-fold higher activity, 8 °C higher melting temperature, 
and new activity for large substrates not found for the base case. A detailed series of initial 
rate experiments allowed us to propose a kinetic mechanism for L-AmDH and showed that 
the mutations which produced the amine dehydrogenase from the parent amino acid 
dehydrogenase also caused changes in the kinetic mechanism. After investigations of 
multiple reactor platforms, enzyme immobilization strategies, and analytical methods, a 
robust packed bed reactor platform was characterized. The accessible design space of the 
reactor was explored. Impacts of flow rate, temperature, substrate concentration, rapid 
recycle, and bed height on conversion, productivity, and enzyme stability were examined. 
The reported work, especially aim 3, fills an important gap in the field. Detailed discussions 
of the impact of physical process parameters on productivity allow for concrete engineering 
decisions. The growing importance of enzymes in pharmaceutical and fine chemical 
production requires an increased focus on biocatalysis from an engineering prospective. 
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CHAPTER 1. INTRODUCTION 
1.1 Motivation 
1.1.1 Chiral Centers in Small Molecule Drugs 
The presence of a chiral center often imposes significant complications and expense 
to the production of an active pharmaceutical ingredient (API), but failure to achieve 
enantiomeric purity can have dire consequences. For molecules with a single chiral center, 
most of physical and chemical properties of the two enantiomers will be identical. 
However, the biological activity of the two compounds can be vastly different. The (R)- 
and (S)- enantiomers of carvone for example smell to humans like spearmint and carraway 
seeds, respectively, due to differences in how the molecules interact with our olfactory 
receptors.3 Just like olfactory receptors, other proteins and enzymes in the body have 
interactions with small molecules that are specific to one enantiomer or the other. For 
example, even though the ubiquitous over the counter analgesic ibuprofen is sold as a 
racemate, it has been shown that only (S)-ibuprofen has the desired pain blocking effects.4 
The metabolic pathways the two enantiomers of ibuprofen become involved in are very 
different, though both forms of the drug are safe. Some chiral drugs, however, not only 
have a single effective enantiomer, but a single safe one. The popular 1950s sleep aid 
thalidomide, sold as a racemic mixture, was found to be responsible for thousands of birth 
defects by the early 1960s.5 Subsequent research over the past 50 years has shown that only 
(S)-thalidomide causes the defects.6 Of the 200 top selling (by total revenue) small 
molecule drugs in 2018, 121 contain at least one chiral center which is not prepared as a 
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racemate.7 For all of the enantiopure drugs on the market today, significant effort in the 
manufacturing process is put into ensuring their chiral purity.  
1.1.2 Prevalence of Chiral Amines in API Manufacturing 
The focus of the work reported in this doctoral thesis is the production of chiral 
amines. Of the top small molecule drugs with nonracemic chiral centers, 27% contain a 
chiral amine functional group such as sitagliptin (Januvia®), clopidogrel (Plavix®), and 
dolutegravir (Tivicay®). A further 25% contain chiral amide groups which have published 
synthetic pathways with intermediates which contain a chiral amine group such as tadalafil 
(Cialis®), ezetimibe (Zetia®), and levetiracetam (Keppra®).8-32 The retail sales revenue 
for each of the six drugs named above was over $1 billion USD in 2018. In total, the 
manufacturing processes of 31.5% of the 200 top selling small molecule drugs, 
representing over $86 billion in sales, required the production of at least one chiral amine.7 
With this large of an existing market, and many more in drug pipelines across the world, 
developments toward more of efficient production strategies for chiral amines create 
impacts on global pharmaceutical manufacturing. 
1.2 Asymmetric Synthesis of Chiral Amines 
When a chiral amine is incorporated into an API, the chiral purity, which is generally 
discussed in terms of enantiomeric excess (% ee), must be greater than 98%, as per FDA 
guidelines (or else a separate toxicology must be presented). Percent enantiomeric excess 
is defined as the absolute percentage difference between the concentrations of the two 
enantiomers in solution, as shown in (1).  
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% 𝑒𝑒 = |
[𝑅] − [𝑆]
[𝑅] + [𝑆]
| × 100% (1) 
A racemate (50:50 mixture of R and S) has 0% ee, a 60:40 mixture of R and S has 
20% ee, and a 99:1 mixture of R and S has 98% ee. Generally, in a classic amination 
reaction from an achiral starting material, the product will be a racemic mixture of R and S 
at the chiral center. However, if the catalysts or substrates in the reaction are chiral, then 
asymmetric synthesis of a single amine enantiomer can be accomplished. For the purposes 
of this discussion, chiral catalysts will be split into two categories: chemical catalysts and 
enzyme biocatalysts. 
Chemical catalysis toward asymmetric amination often utilizes chiral organometallic 
compounds which contain a transition metal like iron, palladium, or iridium. While a 
detailed discussion of chemical amination is outside the scope of this work, the first 13 
chapters of the 2010 book Chiral Amine Synthesis contain hundreds of diverse examples 
which utilize a wide variety of chemistries.33  
Across the natural world, there are countless varieties of enzyme biocatalysts which 
catalyze millions of different biochemical reactions. Because each amino acid residue 
(other than glycine) in a protein is chiral and present as the enantiomerically pure (S)-
isomer, the active sites of enzymes are naturally chiral and bind to ligands and substrates 
in very specific orientations. Enzymes will typically only bind productively to a single 
enantiomer of a chiral substrate. Likewise, if a chiral center is generated in an enzymatic 
reaction, just one enantiomer is typically produced with >99.9% ee. The naturally high 
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enantioselectivity of enzymes is their primary selling point for pharmaceutical production, 
but other advantages are discussed in 1.3.1. 
1.3 Enzymatic Routes to Chiral Amines 
1.3.1 Advantages of Biocatalysis Over Traditional Chemical Catalysis 
The primary advantage of a biocatalytic approach to a reaction over chemical 
catalysis is often specificity and regioselectivity.34 The effects of target reactions resulting 
from an enzyme reaction are typically orders of magnitude less severe compared to other 
catalysts. This can allow for reactions on complex molecules with multiple similar 
functional groups without the need for extensive protection and deprotection steps. The 
operating conditions for biocatalysis can offer significant advantages in terms of safety and 
capital costs as enzymes often operate near ambient temperatures and pressures, with 
moderate pH values in aqueous solutions. Additionally, enzymes are produced from living 
microorganisms which feed on renewable materials and are readily biodegradable.  
1.3.2 ω-Transaminases (ω-TAs) 
1.3.2.1 Reaction 
Thus far, the most widely utilised family of enzymes for the production of chiral 
amines has been the ω-transaminases (ω-TAs).35-36 Key examples APIs whose 
manufacturing processes made use of ω-TAs include UCB’s epilepsy drug levetiracetam 
(Keppra®),37 Merck’s type 2 diabetes drug Sitagliptin (Januvia®),38-40 and suvorexant 
(Belsomra®),41 an insomnia drug also from Merck. As shown in the simple example 
reaction in Figure 1-1, a prochiral ketone is transformed into an enantiomerically pure 
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primary (S) amine with the transfer of the nitrogen from an amine donor and simultaneous 
transfer of the carbonyl between ketone substrate and  amine donor. Common amine donors 
used for ω-transaminase reactions include alanine,42 isopropylamine,43-44 and 
methylbenzylamine. ω-transaminases can also be used in kinetic resolution applications by 
operating in the reverse direction compared to Figure 1-1. 
1.3.2.2 Advantages 
ω-TAs are a highly versatile family of enzymes.45 Both (R)-selective (from 
Aspergillus terrus  and Arthrobacter sp. for example) and (S)-selective (from Arthrobacter 
citreus and Geobacillus thermodenitrificans for example) ω-TAs are available. Primary 
amines anywhere in the structure are accessible. Because of their use in blockbuster drugs, 
some ω-TAs have been heavily engineered to increase their activity, stability, and solvent 
tolerance. To produce an enzyme which was active on their substrate of interest, and was 
stable in 50% dimethyl sulfoxide (DMSO), Merck employed 11 successive rounds of 
directed evolution on the (R)-selective transaminase from Arthrobacter sp. to produce 
sitagliptin.38 Another advantage of ω-TAs over some other enzymes in this list is the lack 
of a requirement for an expensive consumable cofactor. Amine dehydrogenase (1.3.4), 
Figure 1-1 Representative reaction scheme for an ω-transaminase 
 6 
reductive aminase (1.3.3.3), and imine reductase (1.3.3) reactions all require a hydride 
transfer from NADH or NADPH, while ω-TA reactions do not. 
1.3.2.3 Limitations 
The primary limitation to asymmetric amine production with ω-transaminases is 
the often significant thermodynamic limitations in the direction of the desired reaction.46 
Additionally, ω-TA reactions suffer from severe product inhibition limitations.47 To 
combat these limitations, some form of product removal is required to drive equilibrium 
toward chiral amine products. Additionally, the amino donor must be present in the reaction 
in great excess to further drive equilibrium and overcome inhibitions. At small scales, 
multi-enzyme cascades have been employed. In one such scheme, alanine acts as the amino 
donor for the ω-TA and is transformed into pyruvate. Lactate dehydrogenase is then used 
to recycle pyruvate back into lactate. However, because lactate dehydrogenase uses 
NADH, a very expensive cofactor, a third enzyme, glucose dehydrogenase, must be used 
to regenerate NADH from NAD+.42 The addition of two enzymes to the process greatly 
increases complexity and cost, making this approach difficult to scale. In the large-scale 
manufacturing process for sitagliptin, isopropylamine was selected as the amine donor. The 
resulting 2-propanone was evaporated out of the solution as the reaction proceeded, thus 
driving the equilibrium toward product.38 Other groups have used so-called “smart” amine 
donors such as ortho-xylenediamine.42 After the donation of one of its amine groups to the 
reaction substrate, the amine donor forms a transient cyclic imine with the remaining 
nitrogen. This imine spontaneously and nearly irreversibly converts to an aromatic 
isoindole. The isoindole further polymerizes in solution to form a colored precipitate, 
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which can be used as a rapid colorimetric assay to screen large numbers of mutant enzyme 
variants.  
1.3.3 Imine Reductases (IREDs) 
1.3.3.1 Reaction 
Imine reductases (IREDs), as their name suggests, catalyse the reduction of 
prochiral imines to chiral amines. To accomplish this transformation, all natural IREDs 
require a hydride transfer from NADPH (see Figure 1-2A). Recently, multiple groups have 
bene able to engineer an IRED to accept the much cheaper NADH instead of NADPH.48-
49 Most substrates for IRED reactions are secondary cyclic imines which are stable in 
solution. The ability to generate chiral cyclic amines, which are common in APIs is the 
primary advantage of IREDs over the other enzymes described in this section. However, 
amination of ketones with imine reductases to form secondary amines has also been 
reported, though with usually limited conversion (see Figure 1-2B).36, 50 Amination of 
Figure 1-2 Representative reaction schemes for imine reductases. Scheme A denotes 
the availability of both (R)- and (S)-selective IREDs. Scheme B shows the reaction scheme 
for the direct amination of ketones with an alkylamine. 
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ketones is accomplished by taking advantage of the unstable imines which form in free 
solution when ketones are exposed to alkyl amines. The resulting imines can act as 
substrates in the IRED, and their conversion to amines drives the equilibrium nonenzymatic 
imine formation reaction toward the imine direction. More than 1000 putative imine 
reductases have been collected in an imine reductase engineering database.36 
1.3.3.2 Limitations 
While they offer access to unique chemistries compared to oxidoreductases, there 
are significant limitations which must be addressed to make use of IREDs. First, except for 
a couple of recent engineered enzymes, all IREDs require NADPH, which is at least an 
order of magnitude more expensive than NADH. Additionally, the accessible ee values 
vary widely between enzymes and substrates.51 Overall, activity is low for IREDs, which 
requires high loads of enzyme to achieve high conversions. For most IREDs capable of 
reductive amination of ketones, specific activity is low, and ratios of amine to ketone 
required for conversion can be as high as 50:1, which leads to a poor atom economy for 
the chemical process.36 
1.3.3.3 Reductive Aminases (RedAms) 
Recently, a group of fungal enzymes homologous to IREDs have been discovered 
and given the name reductive aminase (RedAm). The first of these enzymes is derived from 
Aspergillus oryzae (AspRedAm).52 What sets RedAms apart from IREDS is their greatly 
enhanced ability to perform reductive amination at much lower ratios of amine to ketone, 
and their broad substrate scope. Alkeu et al. reported the successful production of 37 
different chiral amines including aliphatic, aromatic, and cyclic amines.52 In a study 
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focused on two additional RedAms from Aspergillus terreus and Ajellomyces dermatitidis, 
it was discovered that the fungal RedAms, unlike IREDS, are able to directly bind to 
ketones and facilitate imine formation.53 This is likely why RedAms are so much more 
effective than IREDs at reductive amination. 
1.3.4 Amine Dehydrogenases (AmDHs) 
Amine dehydrogenases are the focus of the work reported in this thesis and are 
briefly discussed here. 
1.3.4.1 Reaction 
Amine dehydrogenases (AmDHs) catalyze the reductive amination of prochiral 
ketones to form chiral amines.54 AmDHs require aqueous ammonia as the nitrogen source 
and a simultaneous hydride transfer from NADH. Typically, AmDH reactions are run 
between pH values of 8.5 and 10, with between 2 M and 4 M of an ammonium salt, usually 
either NH4COOH or NH4Cl. The reaction scheme for the reductive amination of 5-methyl-
2-hexanone to (R)-5-methyl-2-aminohexane is shown in Figure 1-3. 
1.3.4.2 Advantages 
Compared to ω-transaminases, amine dehydrogenases feature a more favorable 
atom economy, due to the direct incorporation of ammonia, rather than taking a nitrogen 
Figure 1-3 Representative reaction scheme for reductive amination of a ketone by an 
amine dehydrogenase 
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group from a sacrificial alkyl amine donor. Additionally, AmDHs are not subject to the 
severe equilibrium limitations of ω-TAs, meaning product through evaporation is not 
required to drive catalysis. The acceptance of NADH by AmDHs serves as a distinct 
advantage over IREDs and AmReds, which both require the more expensive NADPH. 
1.3.4.3 Limitations 
Compared to reductive aminases and transaminases, the range of substrates 
accessible to AmDHs is limited. AmDHs are only capable of producing primary amines 
and are active only on methyl ketones and cyclic ketones. Like reductive amination with 
IREDs and ω-TAs, a great excess of the nitrogen donor is required to drive catalysis. 
Mechanistic studies of the L-AmDH found that the apparent KM value for ammonium 
chloride was higher than the solubility limit for ammonium chloride.55 High concentrations 
of ammonium salts can cause issues for further processing and separations after the 
amination reaction is complete.  
1.4 Generating Chirality from a Racemic Mixture of Amines 
Isolation of a single enantiomer of an amine from a racemic mixture, also known as 
deracemization, provides an alternative to asymmetric synthesis. This can be useful when 
the starting material in a process contains a racemic amine, or when asymmetric amination 
is infeasible or prohibitively expensive. The clear disadvantage of most deracemization is 
that the theoretical yield is limited to 50% which can greatly reduce the overall yield of a 
multi-step API manufacturing process. As the number of steps in a chemical process grows, 
each with their own yield values, so too does the penalty for having a single step with a 
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50% yield. The two main methods of deracemization are kinetic resolution and 
diastereomeric salt separation. 
1.4.1 Diastereomeric Salt Separation 
While most of the physical properties, including solubilities, of the two enantiomers 
of a molecule with a single chiral center are identical, this is not true for diastereomers. 
Though not impossible, the crystallization of a single pure enantiomer from a racemic 
mixture is rare, so separation of racemates by simple crystallization is also rare. However, 
the two different salts formed by the addition of an enantiomerically pure carboxylic acid 
to a racemic amine tend to crystallize separately and have different solubilities. Once the 
pure diastereomer salt is isolated, the resolving agent can be removed with the addition of 
a strong acid. Mandelic acid derivatives are often used to resolve racemic amines.56 
However, the ee of a diastereomer salt separation is not always perfect,57-58 which is not 
acceptable for API manufacturing. 
1.4.2 Kinetic Resolution 
Resolution of a racemic amine can also be accomplished through a reactive process 
where a catalyst is introduced to the racemate which reacts with only one of the 
enantiomers. This is most frequently accomplished enzymatically but can also be done 
chemically. Many of the enzymes described in 1.3 are useful for kinetic resolution in 
addition to asymmetric synthesis. When AmDHs are used for kinetic resolution, a separate 
cofactor regeneration system is required to efficiently oxidize the NADH produced by the 
AmDH back to NAD+,59 a task usually carried out by an NADH oxidase (NOX).60 Recent 
work in the Bommarius group showed higher reaction rates could be achieved for NOX 
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cofactor regeneration if the reaction is carried out under a constant stream of oxygen or air 
bubbles.61 Another class of oxidoreductase enzymes that has shown to be useful for kinetic 
resolution are the monoamine oxidases, which catalyze the oxidative deamination of chiral 
amines.36 
1.4.3 Chemoenzymatic Dynamic Kinetic Resolution 
Chemoenzymatic dynamic kinetic resolution has the capability to get around the 50% 
yield limitation mentioned in 1.4.62 Paetzold and Bäckvall described a process by which an 
enzymatic kinetic resolution with Lipase B from Candida antarctica (CALB) is paired with 
a ruthenium-containing organometallic racemization catalyst.63 The process is given the 
label “dynamic kinetic resolution” rather than just kinetic resolution because the substrate 
is constantly racemized by the metal catalyst in situ while CALB only reacts with one of 
the enantiomers to form the corresponding chiral amide. The theoretical yield of this 
process is 100% with >99% ee. If needed, the chiral amide can be converted back to the 
amine chemically64 or enzymatically65 without sacrificing ee. Purely chemical dynamic 
kinetic resolution of amines has also been reported66 but will not be discussed here in detail. 
1.5 Development, Enhancement, and Utilization of Amine Dehydrogenases 
1.5.1 Generation of L-AmDH from Leucine Dehydrogenase 
The starting point for all engineered amine dehydrogenases is an amino acid 
dehydrogenase (AADH). AADHs catalyze the reductive amination of α-keto acids with 
ammonia to produce α-amino acids. These enzymes are key players in amino acid 
metabolism in all virtually all organisms. Abrahamson started with the crystal structure of 
 13 
the phenylalanine dehydrogenase (PheDH) from Rhodococcus sp. M4 in the holo-form 
with NADH and phenylalanine bound in the active site (PDB ID: 1C1D).67 From this 
crystal structure, key residues responsible for interacting with the substrate in the active 
site were located. Because the goal was to move from activity on keto-acids to ketones, 
special attention was paid to residues which interacted with the carboxylic acid. Because 
of the structural similarity among the family of amino acid dehydrogenases, the key 
residues found in the PheDH could be mapped to similarly located residues on the scaffold 
for the leucine amine dehydrogenase (L-AmDH), a leucine dehydrogenase (LeuDH) from 
Figure 1-4 Residues in the active site of Rhodococcus sp. phenylalanine dehydrogenase 
identified as important for substrate binding (PDB ID: 1C1D). This figure was 
originally printed in Abrahamson’s 2012 article on the L-AmDH.2 
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Geobacillus stearothermophilus. The locations of these important residues can be seen in 
Figure 1-4, from Abrahamson’s 2012 paper.2 The first key residue identified was PheDH 
K67, homologous to K68 in the LeuDH. The side chain of this lysine interacts closely with 
the phenylalanine acid group. A site saturation mutagenesis library was constructed at this 
location. The K68M mutant was found to catalyze the reductive amination of methyl 
isobutyl ketone (MIBK) with very low (0.2 mU/mg) but unprecedented activity.  
Once the first small amount of activity was obtained, a lot of protein engineering 
work was done to enhance that activity to level that could be of use in larger-scale reactions. 
A broader library was created with targeted mutations at each of the marked locations in 
Figure 1-4 using the CASTing approach and the resulting mutants were screened for their 
deamination activity toward 4-methyl-2-aminopentane.68 A quadruple mutant, 
K68S/E114V/N261L/V291C, was produced with significant activity towards MIBK (0.69 
U/mg) and a few other prochiral ketones.  
1.5.2 Building a Family of Amine Dehydrogenases 
Once the first AmDH was created, work in the Bommarius group and around the 
world has been done to generate additional AmDHs with different properties. Two residues 
were identified as being key to L-AmDH binding to ketones, K68 and N261. Residues 
homologous to these in other AADHs have been similarly mutated to produce new amine 
dehydrogenases. To date, amine dehydrogenases have been produced from PheDHs,69-71 
LeuDH,72-74 and a valine dehydrogenase (ValDH) (unpublished). In the Bommarius group, 
the PheDH from Bacillus badius was used as the starting point for the published 
phenylalanine amine dehydrogenase (F-AmDH).69 Additionally, a chimeric AmDH (cFL1-
 15 
AmDH) has been produced in the Bommarius lab by combining the substrate binding 
domain of F-AmDH and the cofactor binding domain of L-AmDH which resulted in an 
enzyme with much greater thermal stability, and a substrate profile different from the 
parent enzymes.75 Recently, Tseliou et al. generated a novel L-AmDH (Le-AmDH) 
through homology modeling of the active site of the ε-deaminating L-lysine dehydrogenase 
from Geobacillus stearothermophilus, which is significantly different in sequence and 
structure from the AADHs which formed the scaffolds for the other engineered AmDHs.76 
Additionally, the wild-type parent enzyme of this AmDH was not capable of asymmetric 
amino acid synthesis, unlike previous AmDH scaffolds. The authors found that this Le-
AmDH showed significantly reduced product inhibition compared to existing AmDHs. 
Finally, Carine Vergne-Vaxelaire’s group has used metagenomic mining to uncover a 
variety of wild-type AmDHs for the first time.77-78 
1.5.3 Modifications to Improve Activity and Stability 
On top of generation of new AmDHs, work has been done in the Bommarius group 
and by others to improve the stability and activity of existing AmDHs. Work toward 
improving the L-AmDH engineered from Geobacillus stearothermophilus LeuDH was 
done by the Bommarius group79 and is reported in CHAPTER 2. Pushpanath et al. 
introduced mutations to the Abrahamson F-AmDH69 in addition to generating an AmDH 
from Caldalkalibacillus thermarum PheDH, with the goal of increasing activity, thermal 
stability, and solvent tolerance. Finally, Chen et al. introduced mutations into the active 
site of an AmDH derived from Lysinibacillus fusiformis LeuDH which reshaped the 
enzyme binding pocket, allowing activity towards aliphatic ketone substrates which were 
too large to bind to the original enzyme.80 
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1.5.4 Cofactor Regeneration 
For all the AmDH reactions studied by the Bommarius and reported in the 
literature, NADH more expensive by far than any other substrate or product. At the time 
of writing, 1 kilogram of the disodium salt of NADH can be purchased from VWR for 
$17,225 USD, which amounts to $12,219 USD per mole. At the same time, 500 mL of 5-
methyl-2-hexanone, the ketone used extensively in CHAPTER 5, can be purchased from 
VWR for $30 USD, which amounts to $3.55 USD per mole. Because of the high cost of 
the cofactor, and because its oxidized form, NAD+ is not a valuable product of the reaction, 
steps must be taken to greatly reduce how much cofactor is needed per mole of amine 
product produced. 
To solve the NADH problem, an additional enzyme is added to the reaction which 
converts NAD+ back to NADH at the expense of some substrate which is much cheaper 
than the cofactor. The two most common enzymes for this purpose are formate 
dehydrogenases (FDH), which convert formate to CO2 and glucose dehydrogenases 
(GDH), which convert glucose to gluconic acid. FDH is generally preferred for AmDH 
reactions due to its more favourable atom economy. Additionally, the reaction of formate 




 is irreversible, which can help to drive the AmDH reaction toward completion, 
potentially overcoming any equilibrium limitations.81 The use of cofactor regeneration is 
ubiquitous in the literature for any enzymatic reaction which requires an NADH or NADPH 
cofactor.82  
In a growing body of work on a variety of enzyme platforms, enzymes which 
require redox cofactors are co-expressed as fusion proteins with a cofactor regeneration 
enzyme. Additionally, the cofactor itself is often covalently attached to the fusion construct 
with a flexible linker, such that the entire enzyme/cofactor system is a single 
macromolecular structure which can be immobilized in a flow reactor setup without the 
need to feed the cofactor.83 Rather than generation of a genetic fusion between the two 
enzymes of interest, other work utilized the SpyTag/SpyCatcher system to generate 
covalent conjugation of the two proteins after enzyme expression.84 The effects of fusion 
on enzymatic activity varies among enzymes, with some seeing improvement, and others 
seeing loss of activity.85  
1.5.5 Utilization in Multi-Enzyme Cascades 
The deamination reactions performed by amine dehydrogenases can be paired with 
other enzymes in series to form multi-enzyme cascade reactions. The first application of 
AmDHs in a cascade reaction was reported by Mutti et al. in 2015.86 In that study, the 
authors coupled an either an (R)-selective or (S) selective alcohol dehydrogenase (ADH) 
with cFL1-AmDH to generate a chiral amine from a chiral alcohol in a one-pot synthesis. 
This work was later expanded upon by Mutti87-88 and others.74, 89 One advantage of the 
ADH-AmDH cascade is that it is redox neutral, because the NADH produced by the ADH 
 18 
reaction is converted back into NAD+ by the AmDH reaction. In 2020, Wang et al. added 
a step to the beginning of the alcohol to amine cascade by utilizing a cytochrome p450 
monooxygenase to produce the racemic alcohols from ethyl benzene.90 AmDHs have also 
been used to regenerate amine donors in ω-transaminase reactions.91 
1.5.5.1 Whole Cell Biocatalysis 
While most of the work on AmDHs has utilized purified enzymes in the solution 
phase, some groups have incorporated whole cell biocatalysis into their multi-enzyme 
cascade schemes. The use of whole cells removes the need for potentially costly and time-
consuming purification protocols. Additionally, cells produce their own cofactors, 
potentially eliminating the need to add exogenous NADH.92 Jeon et al. co-expressed cFL1-
AmDH and the NADH oxidase from Lactobacillus brevis in E. coli BL21 (DE3) cells to 
enable the kinetic resolution of racemic amines, with the best activity seen toward 2-
aminoheptane and methylbenzylamine where 99% ee was achieved after five hours for 
both substrates.60 Liu and Li demonstrated the use of whole cell biocatalysis in an ADH-
AmDH system to enable separate cofactor regeneration systems for each enzyme, with the 
ADH and NADH oxidases inside E. coli cells and AmDH and glucose dehydrogenase in 
free solution.89 In a rather exotic experiment, an L-AmDH produced by Chen et al. was 
paired with a formate dehydrogenase for the amination of ketones and aldehydes. What 
made the study exotic is that formate for the FDH was produced by photosynthetic algae 
rather than feeding it exogenously.93 While interesting, this study is of dubious utility, as 
the resources needed to produce, isolate, and dispose of the algae are likely more expensive 
than just purchasing ammonium formate.  
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1.5.6 Immobilization 
In addition to the work on directly improving existing AmDHs and generating new 
ones, the Bommarius group and others have worked toward increasing their usefulness in 
real-world applications through immobilization of the enzymes on to a wide variety of solid 
supports. Immobilization can offer important benefits over homogenous soluble 
biocatalysis,94 key among them being the ease of separating the enzyme from the reaction 
mixture once the reaction is complete. In homogenous biocatalysis, steps must be taken to 
remove the enzyme from solution prior to further processing. For an immobilized enzyme, 
this separation can be achieved by a simple filtration. A related benefit is that because the 
biocatalyst is easy to separate without damaging the enzymes, is it also much easier to reuse 
over multiple batches or in a continuous reactor. Additionally, immobilized enzymes tend 
to be more stable and less prone to aggregation compared to their free-solution forms.95 
Many different immobilization platforms have been applied to co-immobilized amine 
dehydrogenases and cofactor regeneration enzymes. The Bommarius group and others 
have utilized the 6xHis tag generally used for purification to immobilize the enzyme onto 
solid supports with immobilized transition metal ions. Towards this aim, Liu et al. used 
Ni-NTA functionalized magnetic nanoparticles. Controlled porosity glass with 
immobilized Fe(III) ions have been used for AmDH immobilization in combination with 
formate dehydrogenase and alternatively an alcohol dehydrogenase by the Mutti88 and 
Turner96 groups. Additionally, work presented in CHAPTER 5 outlines the use of a 
polyacrylamide resin functionalized with Ni-NTA for the immobilization of cFL1-AmDH 
and FDH. Other immobilization strategies include encapsulation into titania 
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nanoparticles,97 commercial hydrophobic and covalent supports,73 and noncovalent 
immobilization onto calcium phosphate microparticles using leucine zippers.98-99 
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CHAPTER 2. EXPANDING THE BINDING POCKET OF L-
AMDH TO ACCOMMODATE LARGER SUBSTRATES 
The first portion of this chapter (up to and including section 2.5) was adapted from 
“Separate sets of mutations enhance activity and substrate scope of amine dehydrogenase” 
which was authored by R.D. Franklin et al. and published in ChemCatChem in 2020.79 
2.1 Introduction 
For decades, chiral amine compounds have proven to be key intermediates for 
blockbuster drugs. Many of the top selling small molecule drugs today contain chiral amine 
groups.100 Recently, there has been a growing interest in utilizing biocatalytic reductive 
amination of prochiral ketones to produce chiral amines. Biocatalytic production of chiral 
amines offers distinct advantages over classical heterogeneous catalysis. Key enzyme 
families in the field include ω-transaminases,45 imine reductases,101 reductive aminases,52, 
102 and amine dehydrogenases.36 Amine dehydrogenases (AmDHs), first developed in 
20122, catalyze the reductive amination of prochiral ketones to form chiral primary amines 
with the addition of aqueous ammonia. The reaction is dependent on a hydride transfer 
from NADH to form NAD+ (Figure 2-1). To-date, all the AmDHs engineered from amino 
acid dehydrogenases produce (R)-amines. The first AmDH, called leucine amine 
dehydrogenase (L-AmDH) was developed through targeted libraries of mutations in the 
active site of the leucine dehydrogenase (LeuDH) from Geobacillus stearothermophilus. 
After multiple rounds of mutations, activity toward keto acids was removed, and new 
activity toward ketones was obtained. Since 2012, multiple groups have produced similar 
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amine dehydrogenases from other amino acid dehydrogenase scaffolds69-70, 73, 76, 80, 103-105 
or have identified AmDHs from natural sources.77-78, 106 Others have introduced new 
mutations to increase activity for new substrates by altering the size of the ketone binding 
pocket.80 Still more work has been performed on enzyme immobilization,73, 88, 97-99, 107 rate 
law determination,55 whole-cell biocatalysis,89, 104 and multi-enzyme cascades86, 88, 90-91, 108 
to enable the use of amine dehydrogenases in the large-scale synthesis of chiral amines. 
 
Figure 2-1 Reaction scheme for the reductive amination of amines with AmDH and 
list of relevant ketones 
2.2 Plan for Mutations 
In the present work, we sought to improve the published L-AmDH (referred to here 
as the base case) through two separate sets of mutations. The first group was selected to 
increase activity and stability without necessarily impacting substrate specificity. Position 
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V291 was shown to be important for substrate binding in LeuDH.109 In the base case 
enzyme, this residue was mutated from valine to cysteine. It was speculated that mutating 
back to valine (Figure 2-2A) could positively impact activity. Two residues farther away 
from the active site were also shown to be promising candidates in a 2004 patent on 
mutations in LeuDHs.110 Based on the reported results, F101S and D32A were incorporated 
into the L-AmDH base case.  
 
Figure 2-2 A homology model of the engineered L-AmDH sequence mapped onto a 
published LeuDH structure.  
The homology model of L-AmDH was constructed with SWISS-MODEL111-112 and 
mapped the sequence of the engineered L-AmDH base case (2.3.2.1) onto the published 
cryo-EM structure of the LeuDH from Geobacillus stearothermophilus in the apo form 
(PDB ID: 6ACF).113 Because this structure is in the apo form, the holo-structure the PheDH 
from Rhodococcus sp. (PDB ID: 1C1D)114 was aligned to the homology model, the 
phenylalanine substrate and NAD+ cofactor position from this alignment can give a good 
idea of how the substrate and cofactor would be positioned in L-AmDH. Figure 2-2A 
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shows the positions of D32, F101, and C290 relative to the active site. Figure 2-2B shows 
the positions of L39, A112, and T133 in the active site. 
In the second group of mutations, three residues close to the substrate side chain 
were identified as potential targets for altering the L-AmDH substrate scope. Kataoka and 
Tanizawa found that for G. stearothermophilus LeuDH, L39K and A112G mutations both 
caused major changes in the relative specific activities for different amino acid and keto 
acid substrates.80 Recently, Chen et al. showed mutations homologous to A112G and 
T133G enhanced activity toward larger and bulkier ketones in multiple engineered L-
AmDHs.80 Replacing the residues at positions L39, A112, and T133 with smaller residues 
was hypothesized to enable activity toward larger ketones in our L-AmDH as well. The 
positions of the proposed mutations relative to the substrate binding pocket can be seen in 
Figure 2-2B.  
Combinations of the six proposed mutations were introduced into L-AmDH and the 
resulting variants were screened for activity on a variety of straight and branched methyl 
ketones of different sizes. Other mutations were tested but showed poor results.  
2.3 Materials and Methods 
2.3.1 Materials Used 
Overnight Express™ Instant TB Medium (MilliporeSigma, Burlington, MA, USA), 
sodium chloride 99% (BDH VWR Analytical, Radnor, PA, USA), potassium chloride 
>99% (VWR BDH Chemicals, West Chester, PA, USA), sodium phosphate dibasic 
anhydrous >99% (VWR BDH Chemicals, West Chester, PA, USA), potassium phosphate 
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monobasic >99% (Acros Organics, NJ, USA), imidazole 99% (Alfa Aesar, Heysham, 
England), Ni-NTA agarose resin (MCLAB, South San Francisco, CA, USA), dimethyl 
sulfoxide 99.9% (Fisher Chemical, Fair Lawn, NJ, USA),  LB broth (US Biological, Salem, 
MA, USA), agar (VWR Life Science AMRESCO, Solon, OH, USA),  kanamycin 
monosulfate (GoldBio, St Louis, MO, USA), NADH disodium salt trihydrate 99.6% (VWR 
Life Science AMRESCO, Solon, OH, USA), ammonium chloride 99.5% (VWR Life 
Science AMRESCO, Solon, OH, USA), ammonium hydroxide 28%-30% (Ricca 
Chemical, Arlington TX, USA), QIAprep spin miniprep kit (Qiagen, Hilden, Germany), 
agarose (Fisher Scientific, Hampton, NH, USA), QIAquick gel etraction kit (Qiagen, 
Hilden, Germany), midori green (Nippon Genetics Europe GmbH, Dueren, Germany), tris 
base 99.8% (Fisher BioReagents, Fair Lawn, NJ, USA), ethanol 95% (Decon Laboratories, 
King of Prussia, PA, USA), acetic acid 99.7% (Fisher Chemical, Fair Lawn, NJ, USA),  
FastLink DNA Ligase kit (Lucigen, Middleton, WI, USA), CutSmart® buffer (New 
England BioLabs inc., Ipswich, MA, USA), NdeI restriction endonuclease (New England 
BioLabs inc., Ipswich, MA, USA), XhoI restriction endonuclease (New England BioLabs 
inc., Ipswich, MA, USA), 1 kbp DNA ladder (New England Biolabs, Ipswich, MA, USA), 
Q5 DNA polymerase (New England Biolabs, Ipswich, MA, USA), Deoxynucleotide 
(dNTP) Solution Mix (New England Biolabs, Ipswich, MA, USA), acetone 99.9% (Fisher 
Chemical, Fair Lawn, NJ, USA), 2-butanone >99% (Sigma-Aldrich, St. Louis, MO, USA), 
2-pentanone 99% (Alfa Aesar, Heysham, England), 2-hexanone >98% (TCI Chemical, 
Tokyo, Japan), 2-heptanone 99% (BeanTown Chemical, Hudson, NH, USA), 2-octanone 
>98% (TCI Chemical, Tokyo, Japan), 2-nonanone >98% (Alfa Aesar, Tewksbury, MA, 
USA), 2-decanone 97% (Alfa Aesar, Heysham, England), methyl isopropyl ketone 99% 
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(Sigma-Aldrich, St. Louis, MO, USA), methyl isobutyl ketone >99% (Sigma-Aldrich, St. 
Louis, MO, USA), pinacolone 98% (Sigma-Aldrich, St. Louis, MO, USA), 5-methyl-2-
octanone >80% (TCI Chemical, Tokyo, Japan), 6-methyl-2-heptanone >98% (TCI 
Chemical, Tokyo, Japan), Marfey’s Reagent >95% (TCI Chemical, Tokyo, Japan), 
Acetonitrile HPLC grade (Fischer Chemical, Fair Lawn, NJ, USA), Acetone HPLC grade 
(Fischer Chemical, Fair Lawn, NJ, USA), racemic 2-aminopentane >97% (TCI Chemical, 
Tokyo, Japan), racemic 2-aminoheptnane >98% (Alfa Aesar, Haverhill, MA, USA), (R)-(-
)-2-aminononane >99% (Alfa Aesar, Haverhill, MA, USA), (S)-(+)-2-aminononane >99% 
(Alfa Aesar, Haverhill, MA, USA), benzoyl chloride >99% (Alfa Aesar, Haverhill, MA, 
USA) 
2.3.2 DNA and Amino Acid Sequences 









Note, the numbering convention used in the reported work does not include the His-Tag 
sequence (marked in red) or the N-terminal methionine (marked in green). The exclusion 
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of the starting methionine in numbering is because in E. coli, this residue is cleaved from 
translated proteins by methionyl-aminopeptidase, and thus is not present in the expressed 
protein. 















2.3.2.3 Primers Used 
T7 promoter:   TAATACGACTCACTATAGGG 
T7 Terminator:  GCTAGTTATTGCTCAGCGG 
 28 
D32A Forward:  GTCATTCATGCGACGACGCTCGGC 
D32A Reverse:  GCCGAGCGTCGTCGCATGAATGAC 
L39A Forward:  CTCGGCCCGGCGGCCGGCGGGACGCGC 
L39A Reverse: GCGCGTCCCGCCGGCCGCCGGGCCGAG 
L39G Forward: CTCGGCCCGGCGGGCGGCGGGACGCGC 
L39G Reverse: GCGCGTCCCGCCGCCCGCCGGGCCGAG 
F101S Forward: CTTTCGGCCGGAGCATTCAAGGGCTG 
F101S Reverse: CAGCCCTTGAATGCTCCGGCCGAAAG 
A112G Forward:  CGCTACATTACGGGCGTTGACGTTGG 
A112G Reverse: CCAACGTCAACGCCCGTAATGTAGCG 
T133G Forward: GAAACCGACTATGTCGGCGGCATTTCGCCGG 
T133G Reverse: CCGGCGAAATGCCGCCGACATAGTCGGTTTC 
C290V Forward: GATCAACGCCGGCGGCGTCATCAACGTCGCCGATG 
C290V Reverse: CATCGGCGACGTTGATGACGCCGCCGGCGTTGATC 
2.3.3 Overlap Extension Mutagenesis 
Genes containing desired mutations were generated via overlap extension PCR 
using the primers above. For the first step, parallel PCR reactions were conducted using 
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the T7 promotor and mutagenic reverse primers in one reaction, and the mutagenic forward 
primer and T7 terminator primer in the other reaction. PCR products were purified using 
gel extraction, and then combined in a second PCR with T7 promotor and terminator 
primers. For the second PCR, 5 cycles are completed prior to adding primers in order to 
extend the overlaps in the two gene fragments to form whole a whole gene. The single 
product from the second PCR was purified via gel extraction. Purified gene fragment and 
empty pet28a vector were both restricted with NdeI and XhoI enzymes. Following a third 
gel extraction, gene fragment and cut vector were ligated using the FastLink DNA ligase 
kit from Lucigen and then transformed into chemically competent BL21(DE3) cells. The 
resulting colonies were screened for the successfully inserted gene by colony PCR. 
Validated colonies were grown overnight in 5 mL LB-Kanamycin broth and an aliquot was 
frozen at -80 °C in 10% DMSO. The pet28a plasmid containing the mutant L-AmDH gene 
was extracted from the remainder of the culture using the Qiagen QIAquick spin miniprep 
kit for sequencing and storage. 
2.3.4 Enzyme Expression 
Genes encoding L-AmDH variants were cloned into the pet28a vector and 
transformed into BL21(DE3) competent cells for expression. Frozen cell stocks were 
stored at -80 °C in 10% DMSO. For enzyme expression, a starter culture (5 mL LB with 
25 μg/mL kanamycin) was seeded from the frozen stock and incubated at 37 °C, 250 RPM 
overnight. 500 μL of the starter culture was used to seed 50 mL of sterile Overnight 
Express™ Instant TB Medium with 25 μg/mL kanamycin in a 250 mL baffled flask. The 
full-scale culture was incubated in an orbital shaking incubator at room temperature for 24 
hours. Cells were then isolated by centrifugation at 4000 RPM for 35 minutes. After 
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decanting the supernatant, cell pellets were either harvested immediately for protein 
purification or stored at -80 °C until needed. 
2.3.5 Enzyme Purification 
His-tagged L-AmDH binds tightly and specifically to Ni-NTA IMAC resins, which 
allows for simple purification of the enzyme from other host-cell proteins. Cell pellets were 
resuspended in 10 mL Lysis Buffer (1X PBS, 300 mM NaCl, 10 mM imidazole, pH 7.4) 
and lysed on ice using a probe sonicator for ten cycles of 1 minute/1 minute off. The 
insoluble fraction was removed by centrifugation (10,000 RPM, 4 °C, 40 minutes) and the 
supernatant applied to 2 mL of Ni-NTA agarose resin (MCLAB) which had been pre-
equilibrated with lysis buffer. The His-tagged L-AmDH was incubated with the resin on 
ice for 15 minutes, with gentle resuspension every 3 minutes. The supernatant was drained 
in a small gravity column to waste. The resin is then washed twice, first with 10 mL of 
Wash 1 Buffer (1X PBS, 300 mM NaCl, 20mM imidazole, pH 7.4), followed by 10 mL of 
Wash 2 Buffer (1X PBS, 300 mM NaCl, 40 mM imidazole, pH 7.4). The washing is done 
to remove any non-specifically bound proteins. Finally, the resin was incubated for 5 
minutes at room temperature in the Elution Buffer (1X PBS, 300 mM NaCl, 250 mM 
imidazole, pH 7.4) to recover the desired protein. Enzyme concentration was quantified 
using the Bradford Assay,115 and purity of each step was examined using SDS-PAGE. An 
example gel from the purification of L-AmDH/D32A can be seen in Figure 2-3. 
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2.3.6 Activity Assays 
Specific activity for various ketones was measured with UV-Visible spectroscopy 
(Beckman Coulter DU 800 Spectrometer). Reaction volume was fixed at 1 mL and 
temperature at 1 mL. All reactions were carried out in 4M NH4Cl at pH 9.6, with 200 μM 
NADH, and 20 mM ketone. Stock solutions of 20 mM NADH in deionized water, 4M 
NH4Cl/NH4OH in deionized water, and 1M ketone in DMSO, and enzyme in the elution 
buffer were prepared ahead of time. 6 reactions were prepared in parallel with the addition 
of 20 μL NADH, 10-30 μL enzyme solution, and 20 μL of ketone solution. Reactions were 
initiated by the rapid addition and mixing of enough NH4Cl solution to bring the final 
volume to 1 mL. Reaction rate was determined by the decrease of absorbance of NADH at 
340 nm (340 = 6.22 mM
-1cm-1) for at least 3 minutes. Enzyme concentrations in the 
Figure 2-3 Representative SDS-PAGE gel showing the steps to the purification of an 
AmDH. Specifically, this was a gel collected after the purification of L-AmDH/D32A. The 
dark band at around 40 kDa is the protein of interest. 
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reactions were adjusted to ensure a linear reaction profile over the measurement period. To 
validate the repeatability of the activity assays, selected reactions were performed in 
triplicate. Standard deviations of the initial rate ranged from 2% to 10% of the average 
value, with the larger percent standard deviations found for the low activity substrates. 
2.3.7 Melting Temperature Estimation with Differential Scanning Fluorimetry 
Denaturation temperatures of L-AmDH and L-AmDH-TV were estimated using the 
Prometheus™ NT.48 differential scanning fluorimetry (nanoDSF) instrument from 
NanoTemper. Small samples (10 μL) of protein solutions (~1 mg/mL in elution buffer) 
were heated in the instrument and the difference in fluorescence at 330 nm and 350 nm 
was measured to follow changes in the number of tryptophan residues exposed to solvent. 
The inflection point of the temperature vs florescence curve is the estimated melting 
temperature of the enzyme (see Figure 2-4).  
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Figure 2-4 Melting profiles of L-AmDH and L-AmDH TV. Curves were collected by 
differential scanning fluorimetry with the ~1 mg/mL enzyme samples prepared in 250 mM 
imidazole elution buffer. Points on the curves indicate the measured apparent melting 
temperatures of the enzymes. 
2.3.8 50 mL Scale Conversions 
Selected reactions were carried out at the 50 mL scale to demonstrate the 
improvements in activity towards larger substrates granted by L-AmDH-TV/L39A 
compared to L-AmDH. Substrates selected were 2-pentanone, 2-heptanone, and 2-
nonanone. Substrates 3 and 5 were present at 10 mM, while substrate 7 was present at 2 
mM due to solubility limitations. The reaction buffer also contained 2 M 
NH4COOH/NH4OH buffer at pH 8.5, and 1 mM NAD
+. The formate dehydrogenase from 
Candida boidinii (cbFDH) was used to recycle the cofactor. Amine dehydrogenase and 
cbFDH were each expressed and purified as described above and desalted into 1X PBS 
using PD-10 desalting columns from GE Healthcare. Each reaction contained 2 mg of 
cbFDH and 2 mg of either L-AmDH or L-AmDH-TV/L39A. Conversions were carried out 
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in 50 mL conical tubes at room temperature (~21 °C) for 24 hours while spinning at 20 
rpm in a tube rotator. After 24 hours, conversion was measured via HPLC UV/Vis after 
derivatization with benzoyl chloride, and chiral purity was observed via HPLC UV/Vis 
after derivatization with Marfey’s reagent. 
2.3.9 Derivatization with Benzoyl Chloride 
Derivatization with benzoyl chloride (BzCl) was performed to add a chromophore 
to the amine products and make them detectable via HPLC UV/Vis. To 20 μL of AmDH 
reaction mixture, 10 μL of Na2CO3/NaHCO3 (1M, pH 10.5), 40 μL H2O, and 30 μL BzCl 
stock (50 mM in acetonitrile) were added. The mixture was vortexed for 10 seconds 
followed by a brief spin down to remove any liquid from the tube cap. The derivatization 
reaction was then quenched with 20 μL of HCl (1M) and diluted with 90 μL acetonitrile 
solution (83.33 v/v% in H2O) to bring the final acetonitrile concentration to 50%. Samples 
were centrifuged at 14,500 rpm for 10 minutes to remove any protein in solution. Finally, 
150 μL of each supernatant was transferred to an HPLC vial.  Samples were analyzed by 
reversed-phase HPLC as described in the analytics section. 
2.3.10 Diastereomeric Derivatization with FDAA 
Chiral purity of the amine products was determined by reversed-phase HPLC 
UV/Vis after derivatization with FDAA (1-fluoro-2-4-dinitrophenyl-5-L-alanine amide), 
also known as Marfey’s reagent. Reaction of a chiral amine with the chiral FDAA results 
in one of two diastereomers which can be separated without a chiral column. To 40 μL of 
AmDH reaction mixture, 16 μL of Na2CO3/NaHCO3 (1M, pH 10.5) and 40 μL of FDAA 
solution (15 mM in acetone) were added. After mixing by vortexing, samples were 
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incubated at 50 °C and shaking at 600 rpm for 1 hour. Derivatization reactions were then 
quenched with the addition of 8 μL HCl (4 M) and centrifuged at 14,500 rpm for 10 minutes 
to remove protein. 50 μL of the supernatant was diluted first with 50 μL pure acetonitrile, 
then an additional 100 μL of 50 v/v% acetonitrile in water was added. After filtration 
through a 0.22 μm syringe filter, samples were transferred to HPLC vials and analyzed as 
described in the analytics section. 
2.3.11 Analytics 
All HPLC chromatograms were collected using a YMC® ODS-AQTM column 
(100 x 3.0 mm, 5 μm). With a mixture of ACN and H2O as the eluent. Specific conditions 
for each amine are listed separately. 
2.3.11.1 2-aminononane 
BzCl derivative: 
Eluent ACN/H2O (50/50 isocratic); flow 0.5 mL min
−1; temperature 29 °C; injection 
volume 4 μL; UV detection at λ = 215 nm. Peak at 15.682 minutes was integrated and the 
peak area of the reaction samples was divided by the peak area obtained from the 
derivatization of a 2 mM (R)-2-aminononane standard solution to calculate conversion. 
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FDAA derivative: 
Eluent ACN/H2O (50/50 isocratic); flow 0.75 mL min−1; temperature 40 °C; injection 
volume 10 μL; UV detection at λ = 340 nm. Enantiomerically pure standards were used for 
(R)- and (S)-2-aminononane. The product of the TV/L39A preparative-scale reaction can 
be positively identified as (R)-2-aminononane with an ee% greater than 99%. 
Datafile Name:aminononane batch_2172020_005.lcd
Sample Name:nonane std
































Figure 2-5 Representative chromatogram of the HPLC quantification of 2-





Eluent ACN/H2O (50/50 isocratic); flow 0.5 mL min−1; temperature 29 °C; injection 
volume 4 μL; UV detection at λ = 215 nm. Peak at 7.544 minutes was integrated and the 
peak area of the reaction samples was divided by the peak area obtained from the 
derivatization of a 10 mM racemic 2-aminoheptane standard solution to calculate 
conversion. 










Data3:TV L39A 2-aminononane.lcd PDA Ch2 340nm,4nm 
Data2:(S)-aminononane .lcd PDA Ch2 340nm,4nm 
Data1:(R)-aminononane.lcd PDA Ch2 340nm,4nm 




Eluent ACN/H2O (50/50 isocratic); flow 0.5 mL min−1; temperature 40 °C; injection 
volume 4 μL; UV detection at λ = 340 nm. Peak at 9.564 minutes corresponds to the (R)-
amine, no (S)-aminoheptane was detected in the reaction sample, indicating ee% greater 
than 99%. 
Datafile Name:2-16 MegaBatch_2162020_020.lcd
Sample Name:10 mM 2-aminoheptane




































Eluent ACN/H2O (50/50 isocratic); flow 0.5 mL min−1; temperature 29 °C; injection 
volume 4 μL; UV detection at λ = 215 nm. Peak at 3.269 minutes was integrated and the 
peak area of the reaction samples was divided by the peak area obtained from the 












Data2:TV L39A 2-aminoheptane.lcd PDA Ch2 340nm,4nm 
Data1:Racemic 2-aminoheptane.lcd PDA Ch2 340nm,4nm 
Figure 2-8 Comparison of HPLC chromatograms of 2-aminoheptane derivatized with 
FDAA. The racemic standard (black) showed two peaks of roughly equal size, while 
the 2-aminoheptane produced by L-AmDH TV/L39A produced one peak, indicating 
an ee% greater than 99%. 
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FDAA Derivative:  
Eluent ACN/H2O with a linear gradient (30/70 ratio for 1 minute, then 30/70 to 70/30 in 
14 minutes, then hold at 70/30 for 1 minute); flow 0.5 mL min-1; temperature 40 °C; 
detection at λ = 340 nm. The (R)- and (S)- enantiomers elute at 11.148 minutes and 11.415 
minutes respectively. 
Datafile Name:2-16 MegaBatch_2162020_014.lcd
Sample Name:10 mM 2-aminopentane





















Figure 2-9 Representative chromatogram of the HPLC quantification of 2-
aminopentane derivatized with benzoyl chloride 
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Figure 2-10 Comparison of HPLC chromatograms of 2-aminopentane derivatized 
with FDAA. The racemic standard (Black) showed two peaks of roughly equal size, while 
the two samples from 24-hours enzymatic conversions with L-AmDH (pink) and L-AmDH 
TV/L39A (blue) show just one peak. 
2.4 Results 
The L-AmDH mutations D32A, F101S, and C290V were generated sequentially 
using overlap extension PCR, followed by cloning and protein expression. Specific activity 
toward various aliphatic ketones was measured in 1 mL batch reactions by following the 
decrease in concentration of NADH with UV-visible spectrophotometry and is recorded in 
milliunits per milligram of enzyme, with one unit defined as the amount of enzyme required 
to catalyze the conversion of one micromole of substrate in one minute. The results of these 
assays are recorded in Table 2-1. Across the six substrates for which activity could be 
quantified, the combined D32A/F101S/C290V mutant (L-AmDH-TV) showed an average 
of a 2.5-fold increase in activity compared to the base case enzyme. The largest 
improvement was seen for 4-methyl-2-pentanone where L-AmDH-TV had 3.4-fold higher 
activity than the base case. Interestingly, the relative activity of the enzyme toward 
different substrates did not change due to the mutations, but rather the mutations increased 
activity for all substrates in roughly equal proportions. Additionally, differential scanning 
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fluorimetry (DSF) experiments showed the melting point of L-AmDH-TV to be 73.6 °C, 
an increase of 8.0 °C compared to L-AmDH at 65.6 °C. One possible explanation for the 
stabilization is the introduction of beneficial intermolecular interactions. Positions D32 and 
F101 lie at the interface between monomer subunits in the enzyme quaternary structure. 
Table 2-1 Activity enhancement of L-AmDH toward aliphatic ketones and the 
generation of L-AmDH-TV 
 Specific Activity (mU/mg) 
Substrate L-AmDH D32A D32A/F101S D32A/F101S/ C290V (“TV”) 
1 n.d.[a] n.d. n.d. n.d. 
2 87.9 61.4 181.7 225.5 
3 430.5 888.3 1363.9 1303.6 
4 144.8 172.2 278.6 266.4 
5 n.d. n.d. n.d. n.d. 
6 n.d. n.d. n.d. n.d. 
7 n.d. n.d. n.d. n.d. 
8 n.d. n.d. n.d. n.d. 
9 453.4 945.3 959.2 1146.5 
10 531.1 1406.5 1661.4 1808.5 
11 549.6 1083.3 1145.1 1056.2 
Reaction conditions: 0.4-1.0 µM enzyme, 20 mM substrate, 200 µM NADH, 4M NH4Cl/NH4OH, pH 9.6, 25 °C, 1 mL 
reaction volume. [a] n.d. denotes an activity level below the limit of detection 
Sequence alignments of the active sites of multiple amino acid dehydrogenases 
suggested L-AmDH position L39 as a potential target for expansion of the substrate 
binding pocket to accommodate larger substrates.109 Leucine is conserved at this position 
for leucine dehydrogenases, but a lysine at the homologous position in glutamate 
dehydrogenases is likely responsible for binding the acid group on the glutamate substrate 
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sidechain. The residue is positioned with its side chain pointing in toward the substrate 
binding site. The L-AmDH-TV scaffold presented in the previous section formed the basis 
for further mutations.  L-AmDH-TV/L39A and L39G mutants were produced. Figure 2-11 
shows a comparison of specific activities toward straight-chain ketones of varying lengths. 
For L-AmDH-TV, 2-pentanone shows the highest activity at 1.31 U/mg, while zero activity 
was observed for ketones longer than 2-hexanone. When the leucine at position L39 is 
Figure 2-11 Expansion of the L-AmDH binding pocket to accommodate ketones of 
larger sizes due to mutations at position L39. Reaction conditions: 0.4-1.0 µM enzyme, 
20 mM substrate, 200 µM NADH, 4M NH4Cl/NH4OH, pH 9.6, 25 °C, 1 mL reaction 
volume.   
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replaced with the smaller alanine, activity toward 2-butanone and 2-pentanone are greatly 
reduced, while activity was more than doubled for 2-hexanone. More interestingly, 
TV/L39A showed activity for ketones as large as 2-decanone, with the highest activity 
found for 2-heptanone at 644 mU/mg. When the residue was further mutated to glycine, 
the n-ketone with the highest activity shifted to 2-nonanone. While TV/L39G showed 
decreased activity for 2-butanone through 2-heptanone, activity was increased compared 
to TV/L39A for 2-octanone through 2-decanone. 
Table 2-2 Effects of A112G and T133G on activity toward n-ketones 
 Specific Activity (mU/mg) 











1 n.d.[a] n.d. n.d. n.d. n.d. 
2 225.5 n.d. n.d. n.d. n.d. 
3 1303.6 80.5 565.1 35.1 19.0 
4 266.4 166.6 777.3 308.9 177.7 
5 n.d. 31.9 596.9 446.1 431.5 
6 n.d. n.d. 159.2 268.6 237.4 
7 n.d. n.d. 145.9 268.8 171.2 
8 n.d. n.d. n.d. 140.5 92.9 
Reaction conditions: 0.4-1.0 µM enzyme, 20 mM substrate, 200 µM NADH, 4M NH4Cl/NH4OH, pH 9.6, 25 °C, 1 mL 
reaction volume. [a] n.d. denotes an activity level below the limit of detection.  
Based on results reported for a different set of engineered L-AmDHs,80 A112G and 
T133G were investigated as additional sites for binding pocket expansion. The TV/A112G 
variant shows new activity for 2-heptanone, and a new optimal substrate length of six 
carbons rather than five, as was found for TV (Table 2-2).The further addition of T133G 
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increased activity for 2-pentanone through 2-heptanone, while enabling new activity for 2-
octanone and 2-nonanone. Finally, the addition of L39A to TV/A112G and 
TV/A112G/T133G shifted the optimal substrate length to 7 carbons and enabled activity 
toward 2-decanone. The addition of T133G to TV/L39A/A112G did not have the same 
synergistic effects as were found when TV/A112G, suggesting that the benefits of L39A 
and T133G are not additive. 
Table 2-3 Activity of L-AmDH variants toward long branched ketones 
Enzyme Variant Activity Toward 12 (mU/mg) 
Activity Toward 13 
(mU/mg) 
TV n.d.[a] n.d. 
TV/L39A n.d. n.d. 
TV/L39G n.d. 39.4 
TV/A112G n.d. n.d. 
TV/A112G/T133G n.d. n.d. 
TV/L39A/A112G 258.8 186.4 
TV/L39A/A112G/T133G 177.9 161.5 
Reaction conditions: 0.4-1.0 µM enzyme, 20 mM substrate, 200 µM NADH, 4M NH4Cl/NH4OH, pH 9.6, 25 °C, 1 mL 
reaction volume. [a] n.d. denotes an activity level below the limit of detection.  
The reported variants were also tested for their ability to convert longer branched 
ketones, 12 and 13 (Table 2-3). The combination of L39A and A112G allowed for the 
conversion of these bulky ketones, while each mutation on its own was insufficient. 
TV/L39G also showed low but measurable activity toward 13 at 39.4 mU/mg. As seen with 
the straight-chain ketones, T133G does not increase activity for larger substrates when in 
combination with L39A. 
To further demonstrate the improvements to the applicability of L-AmDH to 
convert larger ketones, selected substrates were converted at a 50 mL preparative scale for 
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24 hours with both L-AmDH and TV/L39A. As shown in Table 2-4, relative conversion, 
(measured after derivatization with benzoyl chloride77) between the two enzymes was in 
line with their relative specific activities. Additionally, the already exquisite 
enantioselectivity of the L-AmDH2 was not impacted by the mutations, as measured after 
diastereomeric derivatization.116 Chromatograms in Figure 2-10 of the derivatized products 
from L-AmDH and L-AmDH-TV/L39A conversions to 2-aminopentane show no 
difference in enantioselectivity of the two variants. The lack of a second peak in both 
reaction samples indicates an ee% greater than 99%. The data shows there are no 
significant differences from previously reported results on L-AmDH due to the mutations.  
A racemic standard was used, but it is assumed that the first eluting peak is the due to the 
(R)-amine, as is shown for 2-aminononane.  Aggregation occurred in all samples occurred 
over the course of the reaction and likely limited overall conversion. In the future, this 
could be mitigated through immobilization. 
Table 2-4 Conversion values for preparative-scale reactions 
  Conversion after 24 hours 
Substrate Concentration L-AmDH TV/L39A 
3 10 mM 65.4 ± 2.2% 48.5 ± 1.6% 
5 10 mM 1.7 ± 0.1% 56.3 ± 4.4% 
7 2 mM n.d. 51.9 ± 0.5% 
Reaction conditions: 2 mg each of AmDH and cbFDH, 1 mM NAD+, ketone concentration as listed, 2M 
NH4COOH/NH4OH, pH 8.5, 21 °C, 50 mL reaction volume, rotating at 20 rpm for 24 hours.  
 
2.5 Conclusion 
In conclusion, we found two sets of mutations to improve L-AmDH which result in 
either increased specific activity and thermodynamic stability, or in an altered substrate 
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specificity towards longer or branched methylketones. While the first set of mutations acts 
synergistically to increase L-AmDH activity and stability, the second set of three mutations 
for change substrate specificity does not. Instead, that second set enables picking a desired 
specificity trait, such as a long side chain of a methylketone or branched 
alkylmethylketone, with a specific mutation. Thus, the current work is an important step 





CHAPTER 3. MECHANISTIC INSIGHT INTO AMINE 
DEHYDROGENASE KINETICS 
The first portion of this chapter (up to and including section 3.5) is adapted from 
“Engineered amine dehydrogenase exhibits altered kinetic mechanism compared to parent 
with implications for industrial application”, which was authored by R.D. Franklin et al. 
and published in Chemical Engineering Journal in 2019.55 
3.1 Introduction 
Amine Dehydrogenases (AmDHs) were first engineered in 20122 and catalyze the 
reductive amination of prochiral ketones to chiral amines and the oxidative deamination of 
primary (R)-amines to ketones. Because chiral amines are precursors for numerous active 
pharmaceutical ingredients (APIs) and enzymes promote intrinsic enantioselective 
chemistry, a requirement for chiral drug molecules, interest in the biocatalytic production 
of these amine compounds has been steadily growing for the past decade.82, 100, 117 
Biocatalytic production of APIs has key advantages over chemical catalysis: operating 
conditions close to physiological conditions, temperatures below 50° C with pressure 
commonly at 1 bar, sustainable catalyst production in bacteria, absence of toxic metals, 
and high enantioselectivity. In addition to engineered AmDHs, wild AmDHs,106 ω-
transaminases,118-119 and recently reductive aminases52 have proven useful for conversion 
of ketones to chiral amines. 
 An AmDH is engineered by mutating two conserved amino acid residues in the 
active site of an amino acid dehydrogenase (AADH). Starting from the leucine 
 49 
dehydrogenase (LeuDH) from Bacillus stearothermophilus, substituting a serine and 
leucine at the K68 and N261 positions, respectively, resulted in the leucine amine 
dehydrogenase (L-AmDH).2 More than a dozen different AmDHs have since been 
generated by applying homologous mutations to AADHs.54, 69-70, 103-104 In the balanced 
reaction for L-AmDH in Figure 3-1, 2-pentanone (Pent) is reductively aminated to form 
(R)-2-aminopentane (AmPent). The reaction for LeuDH, also shown in Figure 3-1, is the 
reductive amination of ketoleucine (KLeu) to (S)-leucine (Leu). For both enzymes the 
NADH cofactor is oxidized to NAD+ through the hydride transfer step.114 
 
The present work lays the groundwork for reactor engineering, required for proper 
scaling of synthesis. An enzyme’s kinetic mechanism (the order and manner of substrate 
binding and product release) determines its kinetic rate law. The rate law defines the 
turnover rate as a function of substrate concentration and is required for the reactor design 
equations, which are used to determine proper reactor size and to predict yield. We have 
used the method of initial rates described by Cook and Cleland120 to propose rate laws for 
both the reductive amination and oxidative deamination reactions for L-AmDH and 
Figure 3-1 Balanced reactions for the leucine dehydrogenase (LeuDH) from Bacillus 
stearothermophilus and the engineered leucine amine dehydrogenase (L-AmDH) 
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LeuDH. As their primary sequence differs by only a few amino acid residues, the kinetic 
mechanism of the engineered L-AmDH was assumed to be the same as its parent. However, 
the results of the present study surprisingly show that the mechanisms and thus the rate 
laws of the two enzymes are different.  
Often, viscogens (i.e. small sugars and sugar alcohols) are included in large-scale 
reaction solutions for enzyme stability and can affect overall enzyme reaction kinetics by 
way of a kinetic solvent viscosity effect (KSVE).121 These KSVEs are often the result of 
either an enzyme conformational change or the rate-limiting diffusion of substrates or 
products to or from the enzyme. Therefore, the potential impact of these KSVEs on the 
industrial scale is examined through the addition of viscogens to small-scale reactions. 
3.2 Materials and Methods 
3.2.1 Materials Used 
L-leucine 99% (Aldrich Chemical Company, Inc, Madison, WI, USA), 4-Methyl-
2-oxopentanoic acid sodium salt >98% (Acros Organics, Morris, NJ, USA), 2-
aminopentane >98% (Tokyo Chemical Industry, LTD., Tokyo, Japan), 2-pentanone 99% 
(Alfa Aesar, Tewksbury, MA, USA), sodium chloride 99% (BDH VWR Analytical, 
Radnor, PA, USA), tris base 99.8% (Fisher BioReagents, Fair Lawn, NJ, USA), 
ammonium chloride 99.5% (VWR Life Science AMRESCO, Solon, OH, USA), glycine 
98.5% (Fisher BioReagents, Fair Lawn, NJ, USA), glycerol 99.9% (Fisher Chemicals, Fair 
Lawn, NJ, USA), sucrose 99.9% (VWR International, Radnor, PA, USA), NADH 
disodium salt trihydrate 99.6% (VWR Life Science AMRESCO, Solon, OH, USA), NAD 
trihydrate >98% (Gold Biotechnology, St Louis, MO, USA), xylitol 99% (Alfa Aesar, 
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Lancaster, United Kingdom), Overnight ExpressTM Instant TB Medium (Millipore Sigma, 
Burlington, MA, USA) 
3.2.2 Enzyme Expression 
Genes encoding leucine dehydrogenase (LeuDH) from Bacillus 
stearothermophilus (EC 1.4.1.9) and leucine amine dehydrogenase (L-AmDH, primary 
sequence as previously reported2) were codon-optimized for expression in E. coli, cloned 
into the pet28a expression vector, and stored in BL21(DE3) cells. Enzymes were expressed 
and purified using standard procedures described previously105 with the modification that 
Overnight ExpressTM autoinduction media was used for growth. His-tagged enzymes were 
purified using Ni-NTA resin. 
3.2.3 Spectrophotometer Assays 
 Solutions of the following were prepared: keto-substrate/amino-substrate (0.15 mM 
– 200 mM), ammonia (125 mM – 4000 mM), enzyme (0.01 μM – 0.3 μM); and NAD(H) 
(12.5 μM – 1000 μM). The reaction was initiated by addition of buffer, and the ΔA340 was 
monitored for 30 seconds at 25°C using a Cary 8454 UV-Vis (Agilent Technologies, Santa 
Clara, CA) equipped with a Quantum Northwest TC 1 Temperature Controller. Cofactor 
and enzyme solutions were kept on ice, buffer solutions were kept in a thermocycler at 
25°C. Cuvettes were prepared with 1% (v/v) cofactor solution and 2% (v/v) enzyme 
solution with a final volume of 700 μL. Enzyme and cofactor were placed in the cuvette 
first, on opposite sides of the cuvette floor to prevent mixing, before the insertion of buffer 
and final mixing of all three solutions. Test reactions with the lowest substrate 
concentrations were conducted for 120 seconds ensure linearity over the target experiment 
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time. If the rate was constant over 120 seconds, then the rate over 30 seconds could be 
assumed to approximate an initial rate. 
3.2.4 Plate Reader Assays 
The reaction was initiated by the addition of buffer to droplets of cofactor and 
enzyme sitting on opposite sides of the well floors, and the ΔA340 was monitored for 60 
seconds at 25°C using a BioTek Synergy H4 Hybrid Reader (BioTek Instruments Inc., 
Winooski, VT). Cofactor and enzyme solutions were kept on ice, buffer solutions were 
kept in a thermocycler at 25°C. Plate wells were prepared with 1% (v/v) cofactor solution 
and enzyme (0.01 μM – 0.3 μM) solution to a final volume of 200 μL. The reactions were 
initiated with the addition of buffer solution containing the keto/amine substrate and 
ammonia to the enzyme and cofactor solutions. Test reactions with the lowest substrate 
concentrations were conducted for 120 seconds to ensure linearity over the target 
experiment time. If the rate was constant over 120 seconds, then the rate over 60 seconds 
could be assumed to approximate an initial rate. 
3.2.5 Nonlinear Fitting to Find Rate Equation 
 For all enzyme assays, plots of initial absorbance vs time data were best fit to linear 
curves and converted to specific activity using Beer’s law (ε340(NADH) = 6.22 mM
-1 cm-
1) and the enzyme concentration. For all subsequent data analyses these specific activities 
were fit using the standard nonlinear model fitting function (NonlinearModelFit[]) in 












𝐾𝑖𝑞𝐾𝑝 + 𝐾𝑞[𝑃] + 𝐾𝑝[𝑄] + [𝑃][𝑄]
     (3) 
Where vo = specific activity, A = NADH, B = 2-pentanone or ketoleucine, C = NH4Cl, P = 
2-aminopentane or leucine, and Q = NAD+. Coeffx terms denotes binary complexes of 
enzyme and X, while Kx is the Michaelis complex for X and corresponds to complexes 
with enzyme and all substrates besides X. Kiq is the dissociation constant for substrate Q. 
Terms in the denominators of these equations were excluded from the model if the 
parameter value was less than zero, or the P-value for the parameter supplied by the fit 
function was less than 0.05 and their removal did not increase the mean squared error of 
the fit. 
3.2.6 Kinetic Solvent Viscosity Effect Determination 
Solvent viscosity was modulated through the addition of glycerol (0% - 30% v/v) 
to the reaction buffers. Viscosity was measured with a size 50 CANNON-Fenske Routine 
capillary viscometer in a water bath kept constant at 25 °C with an ANOVA® Precision 
Cooker. Density was measured with a handheld densitometer (Anton Paar, Graz, Austria). 
Solutions were prepared and incubated at 25 °C in an orbital shaker for 20 minutes. Assays 
were conducted using an Agilent Cary 8454 UV-Vis Diode Array System fitted with a 
temperature-controlled cell holder fixed at 25 °C. Initial rates were best fit to the Michaelis 
Menten equation. The resulting appkcat and 
appkcat/
appKM values were normalized by dividing 
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the value obtained with no added viscogen by the value obtained at a higher viscosity, e.g. 
(appkcat)0/(
appkcat)η. Viscosity was normalized by dividing the viscosity of the glycerol 
solution by the viscosity of reaction buffer with no viscogen. Plots of normalized rate 
constants versus normalized viscosity were fit to equation 4 if the relationship was linear, 
and equation 5 if the relationship had an inverse hyperbolic shape.121 
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1 + 𝐴 [
𝜂𝑟𝑒𝑙 − 1
(𝜂𝑟𝑒𝑙 − 1) + 𝐵
]
   
(5) 
In equations 4 and 5, k is the rate constant in question, ηrel is the relative viscosity, 
and m, A, and B are parameters which describe the shape of the curve. 
3.2.7 Product Inhibition 
Initial reaction rates were collected at varying levels of inhibitor and substrate of 
interest. Other substrates were held at saturating levels whenever possible. The data of each 
single set of experiments were best fit to either the rate equations for competitive (Equation 
6), noncompetitive (Equation 7), or uncompetitive (Equation 8) product inhibition120 in 



































In the above equations (6, 7, 8), v0 = reaction rate, 
appkcat = the first-order rate 
constant, E0 = enzyme concentration, [S] = substrate concentration, KM = Michaelis 
constant, [I] = inhibitor concentration, Kii = the inhibition constant for intercept effects, 
and Kis = the inhibition constant for slope effects. 
3.3 Results 
3.3.1 Global Fit for the Reductive Amination Rate Law 
To develop a kinetic rate law for LeuDH and L-AmDH, initial rates in the reductive 
amination direction at varied concentrations of NH4Cl, keto/keto acid, and NADH were 
best fit to Equation 2 using the method described by Cleland120. Terms in the denominator 
were omitted from the rate law based on their statistical significance (as defined by the P-
value). Results of these fits are shown in Table 3-1. In the global fit for LeuDH, the constant 
term and Coeffb were found to be insignificant (P = 0.486 and 0.763, respectively) and 
were excluded from the final model. This result implied a lack of both a quaternary 
complex and binary enzyme-ketoleucine complex in solution. In the amination direction 
for L-AmDH, the constant term and Coeffc term were found to be insignificant (P = 0.561 
and 0.395, respectively) and were excluded from the final model. Omission of the constant 
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term corresponds to the lack of the quaternary complex and the binary enzyme-NH3 
complex in solution. 
Fit parameters are the constant terms from (2). A=NADH, B=2-pentanone (L-
AmDH)/leucine (LeuDH), C=NH4Cl. Vmax is reported in terms of specific activity. 
Reaction conditions for L-AmDH: 4000, 2000, 1000, 500, 250, and 125 mM 
NH4Cl/NH4OH, 100, 50, 25, 12.5, 6.25, and 3.125 mM 2-pentanone, 0.4, 0.2, 0.1, 0.05, 
0.025, and 0.0125 mM NADH. Assays were run at 25 °C in with a constant pH of 8.5 and 
ionic strength maintained at 4M using NaCl. Reaction conditions for LeuDH: 4000, 2000, 
1000, 500, 250, and 125 mM NH4Cl/NH4OH, 4, 2, 1, 0.5, 0.25, and 0.125 mM ketoleucine, 
0.4, 0.2, 0.1, 0.05, 0.025, and 0.0125mM NADH. Assays were run at 25 °C in with a 
constant pH of 8.5 and ionic strength maintained at 4M using NaCl. MSE indicates the 
mean square error of the fit results. 
The high values for appKM,NH4 prevented determination of the true value of kcat for 
either enzyme. The solubility of ammonium chloride in solution was observed to be around 
6000 mM, so measurement of enzyme activity at [NH4Cl] > 
appKM,NH4 value was not 
possible. Note also the general trend of smaller appKM values in the case of LeuDH when 
compared to L-AmDH, indicating stronger substrate binding. 
3.3.2 Global Fit for the Oxidative Deamination Rate Law 
For the deamination of leucine by LeuDH, no terms were excluded from the final 
model (Table 3-2), which was consistent with a sequential mechanism. For the deamination 
Table 3-1   Global rate law fit parameters for reductive amination by L-AmDH and 
LeuDH 
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of (R)-2-aminopentane by L-AmDH, the constant term was found to be insignificant (P = 
0.637) and was excluded from the final model. This corresponds to the lack of a ternary 
complex in solution. 
Fit parameters are the constant terms from (3). P=leucine (LeuDH)/(R)-2-aminopentane 
(L-AmDH), and Q=NAD+. Vmax is reported in terms of specific activity. Assays were 
carried out at 25 °C in 500 mM Tris/HCl buffer at pH 8.5 with a constant ionic strength of 
4 M, adjusted with NaCl. Substrate concentrations for LeuDH: 4, 2, 1, 0.5, 0.25, and 0.125 
mM leucine, 0.4, 0.2, 0.1, 0.05, 0.025, and 0.0125 mM NAD+. Substrate concentrations for 
L-AmDH: 200, 100, 50, 25, and 12.5 mM 2-aminopentane (racemic), 0.4, 0.2, 0.1, 0.05, 
0.025 mM NAD+. MSE indicates the mean square error of the fit results. 
3.3.3 First- and Second-Order Rate Constants 
The first- and second-order rate constants for both enzymes are listed in Table 3-3. 
For deamination, both enzymes had similar appkcat values. However, the maximum 
amination rate for L-AmDH was 30-fold lower than the value for LeuDH.  The appkcat-
/KM,NH4 and 
appkcat/KM,NADH values both were 50-fold higher in LeuDH than L-AmDH, 
Table 3-2  Global rate law fit parameters for oxidative deamination by L-AmDH and 
LeuDH 
Table 3-3  Comparison of first and second order rate constants between L-AmDH 
and LeuDH 
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however, the appkcat/KM,keto value was 1000-fold higher for ketoleucine than for 2-
pentanone. In the deamination direction, the appkcat/KM,NAD was the same across both 
enzymes, while the appkcat/KM,Leu again was almost 3 orders of magnitude larger than 
appkcat-
/KM,AmPent. These results countered the hypothesis that weak ammonia binding was the 
greatest driver of decreased enzyme activity; instead, the binding of the keto substrate had 
the greatest effect. 
3.3.4 Product Inhibition 
Product inhibition studies were conducted in the reductive amination direction to 
elucidate the binding order of the cofactor and keto substrates. For LeuDH, leucine was 
found to be uncompetitively inhibitive to NADH; for L-AmDH, 2-aminopentane 
noncompetitively inhibited NADH. Aside from that distinction, the inhibition profiles of 
the two enzymes are the same. Competitive inhibition of NAD+ on NADH was found for 
both enzymes. Additionally, the amino product for both enzymes was found to be a 
competitive inhibitor for the keto substrate. The inhibition ratios (KM/KI) for the L-AmDH-
catalyzed reaction (Table 3-4) showed a decrease in reaction efficiency when compared to 
LeuDH. The inhibition ratio describes the ratio of the amount of substrate needed to 
saturate the enzyme versus the amount of product which becomes strongly inhibitory; at 
higher values, less product per enzyme per unit time can be produced. Product inhibition 
by both the cofactor and amino products was stronger for the engineered enzyme. For 
experiments with 2-aminopentane, only a racemic mixture was available. For the results in 
Table 3-4, it was assumed that (S)-2-aminopentane did not interact with the enzyme. If (S)-




C=competitive inhibition, NC=noncompetitive inhibition, UC=uncompetitive inhibition. 
Inhibition constants correspond to the constant parameters in Equations (6), (7), and (8). 
The inhibition ratio (KM/KI) is reported in cases where competitive inhibition was observed. 
3.3.5 Kinetic Solvent Viscosity Effects 
Glycerol was included to increase buffer viscosity and the resulting effects on kcat 
and kcat/KM were observed to determine the differences, if any, in the dependence of the 
rate-limiting steps of L-AmDH and LeuDH on diffusion. For LeuDH-catalyzed 
deamination, appkcat/KM,Leu increased with viscosity in an inverse hyperbolic pattern, while 
the kcat value was not dependent on viscosity (Figure 3-2B). For amination of ketoleucine 
by LeuDH, the kcat/KM,KLeu again exhibited an inverse hyperbolic KSVE and overall 
turnover was mostly limited by diffusion, with a slope of 0.7 (Figure 3-2A). For amination 
with L-AmDH, the appkcat/KM,AmPent value was not viscosity dependent but the 
appkcat value 
was (Figure 3-2C). In the deamination direction, the kcat/KM value was viscosity dependent 
with a slope of 0.76 and the kcat value was not viscosity dependent (Figure 3-2D), a reversal 
of the KSVE on kcat/KM compared to LeuDH. The KSVEs on LeuDH catalysis suggested 
that a diffusion-dependent conformational change was required for turnover but did not 
limit the overall rate. A similar conformational change for L-AmDH was not indicated. 
Table 3-4  Summary of product inhibition patterns for LeuDH and L-AmDH 
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3.4 Discussion 
The differences in the kinetic properties of L-AmDH and LeuDH presented herein 
reflect a different kinetic mechanism. When compared to its parent enzyme, L-AmDH 
Figure 3-2 Kinetic Solvent Viscosity Effects on L-AmDH and LeuDH. Normalized 
reaction rate constants versus normalized viscosity. Dashed gray lines with slope = 1 
represents complete diffusion control. Dashed gray lines with slope = 0 represents no 
impact of diffusion. Circles and solid lines represent effect on appkcat. Squares and dashed 
lines represent effect on appkcat/KM for the indicated substrate. For all experiments, 
glycerol concentrations used were 0%, 7.5%, 15%, 22.5%, and 30% V/V with temperature 
fixed at 25 °C. Individual conditions: A) amination of ketoleucine. 4.8, 2.4, 1.2, 0.6, 0.3, 
0.15, and 0.075 mM ketoleucine, 2.4 M NH4Cl, 200 μM NADH, pH 8.5. B) deamination 
of leucine. 20, 10, 5, 2.5, 1.25, 0.625 mM leucine, 200 μM NAD+, 500 mM glycine buffer, 
pH 9.5. C) amination of 2-pentanone. 100, 50, 25, 12.5, 6.25, 3.125 mM pentanone, 2.4 M 
NH4Cl, 200 μM NADH, pH 8.5. D) deamination of (R)-2-aminopentane. 200, 100, 50, 25, 
12.5, 6.25 mM 2-aminopentane (racemic), 200 μM NAD+, 500 glycine buffer, pH 9.5. 
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displayed a different substrate binding order, lower affinity for the keto substrate, and 
stronger product inhibition. The two key residues which must be mutated to produce an 
AmDH from an amino acid dehydrogenase (K68 and N261 for L-AmDH) form hydrogen 
bonds with the acid group on the substrate.2 The mutations to serine and leucine, 
respectively, permit the binding of methyl ketones but with lower affinity compared to keto 
acids (Table 3-1). The second-order rate constants for pentanone and 2-aminopentane are 
both three orders of magnitude lower than those for leucine and ketoleucine. Additionally, 
solvent viscosity effects demonstrated that an isomerization of the enzyme-substrate 
complex, important for LeuDH catalysis, was not observed for L-AmDH, likely owing to 
a change in rate-limiting step from LeuDH to L-AmDH functionality.  
 Poor NH3 binding was previously hypothesized to cause the 30-fold decrease in 
activity between L-AmDH and LeuDH.123 However, at reaction conditions relevant for 
large-scale synthesis, i.e. high concentrations of all substrates and pH value of 8.5, the 
KM,NH4 values for LeuDH and L-AmDH are much closer than had been expected based on 
reports at pH ~9.6, where KM,NH4 values of < 300 mM were reported for LeuDHs.
124-126 
Since the calculated KM,NH4 value for each enzyme was near the solubility limit of NH4Cl 
of ~6 M, saturating conditions for NH4Cl substrate could not be realized. The large KM,NH4 
values paired with the lack of a constant kinetic term for LeuDH or L-AmDH suggests that 
ammonia in neutral or ionic form (NH3 or NH4
+) does not bind to the enzyme at all, but 
rather that free ammonia attacks the bound ketone or keto-acid directly, as previously 
proposed for PheDH127 and glutamate dehydrogenase (GluDH).128  
The pH value of 8.5 was chosen for the present study to match the pH value for 
large-scale synthesis, where a cofactor regeneration enzyme must be employed to 
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economize cofactor use and to drive high conversion. The most common of these 
regeneration enzymes are formate dehydrogenase (FDH), with a pH optimum around pH 
7.5,129 and glucose dehydrogenase (GDH), with a pH optimum of 8.5.130 Additionally, L-
AmDH and FDH are destabilized at higher pH values (unpublished data). Both L-AmDH 
and LeuDH have lower activity at pH 8.5 than at pH 9.6, the most common pH value for 
conversions with AmDHs.80, 103-104 The pH optima of ketoleucine amination and leucine 
deamination for LeuDH are at pH 9.5 and pH 11, respectively.131 The pKa value for 
ammonium at ionic strength of 4 M is around pH 9.7,132-133 so at pH 8.5 the protonated 
form (NH4
+) dominates, which contributes to the high values of KM,NH4. A standard ionic 
strength of 4 M, (equal to the maximum NH4Cl concentration used), was maintained for 
Figure 3-3 Effect of increasing ionic strength on the kinetic parameters for reductive 
amination of 2-pentanone by L-AmDH. 
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both amination and deamination, as a change of 1.5 M ionic strength can double/half the 
KM,keto value (see Figure 3-3) 
The results for the kinetic mechanism of LeuDH are consistent with previously 
reported data, except for the observed competitive inhibition by leucine on ketoleucine 
(Table 3-4). For reductive amination, there is wide agreement for a strictly ordered 
sequential mechanism of substrate binding, though the exact order has not been consistent. 
There is broad agreement that NAD(P)H binds first, supported by the observation of 
competitive inhibition between NAD(P)+ and NAD(P)H, indicating both forms of the 
cofactor can bind to free enzyme. For LeuDH124-126, 134, AlaDH135-136, and PheDH114, 137-138, 
previous studies have indicated that ammonia binds either second or third. Other than the 
lack of the constant term in the reductive amination direction (Table 3-1), the fitted rate 
laws for LeuDH in both directions are consistent with an ordered sequential mechanism in 
which NADH binds first, followed by ketoleucine, and then ammonia. This binding order 
is consistent with the lack of a [B] term in the denominator of the rate equation, i.e. absence 
of an enzyme-ketoleucine complex, and has been proposed for other leucine 
dehydrogenases.126, 134  
For reductive amination by L-AmDH, the term related to the enzyme-ammonia 
complex is excluded rather than the enzyme-pentanone term (Table 3-1). If this were an 
ordered mechanism, this would imply ammonia binds second, after NADH and before 2-
pentanone. However, a large KM,NH4 value renders ammonia binding to the enzyme itself 
unlikely. More likely, the mechanism calls for ordered addition of ammonia after 2-
pentanone, whereas NADH and 2-pentanone bind randomly. Product inhibition patterns 
(Table 3-4) gave further insight into substrate binding order for LeuDH and L-AmDH. For 
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L-AmDH, competitive inhibition observed for NAD+ on NADH is consistent with previous 
observations for other amino acid dehydrogenases.114, 124, 139 However, competitive 
inhibition observed by 2-aminopentane on 2-pentanone at both half and full saturation of 
NADH has not been reported previously for amino acid dehydrogenases and indicates 
random binding of NADH and 2-pentanone. Additionally, the presence of noncompetitive 
inhibition by NAD+ on 2-pentanone and 2-aminopentane on NADH suggests the presence 
of dead-end complexes of enzyme-NADH-aminopentane and enzyme-NAD+-pentanone. 
Because an uncompetitive inhibitor cannot bind to the free enzyme, the lack of 
uncompetitive inhibition by 2-aminopentane on NADH at saturated 2-pentanone in the 
reductive amination direction rules out a kinetic mechanism where the cofactor must bind 
first.140 For LeuDH, an ordered sequential mechanism was expected based on the 
literature124-126, 134. For a strictly ordered mechanism, uncompetitive inhibition is expected 
for all pairs listed in Table 3-4 except for NAD+ versus NADH, as observed for the LeuDH 
from Bacillus sphaericus.124 Instead, we see competitive inhibition for leucine versus 
ketoleucine and noncompetitive inhibition for leucine versus NADH, which indicates that 
cofactor binding is not necessarily required for leucine binding.  
L-AmDH and parent LeuDH differed in response to increasing solution viscosity, 
indicating a change in the rate-limiting steps of catalysis. For LeuDH, both the amination 
and deamination directions showed an inverse hyperbolic viscosity effect on normalized 
appkcat/KM value for the amino/amino acid substrate. An inverse hyperbolic KSVE indicates 
that an isomerization of the enzyme-substrate or enzyme-product complex contributes to 
catalysis.121 The kcat value encompasses all first-order rate constants in the reaction while 
the kcat/KM value reflects all kinetic steps starting from binding of the substrate to the first 
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irreversible step. If the effects on the kcat and kcat/KM values were the same, then the rate-
determining step would occur between substrate binding and the first irreversible step.120 
However, because the KSVEs were different, kcat reflects a step that occurs after the first 
irreversible step (likely the product release step). Because the effect on appkcat/KM was 
hyperbolic rather than linear, diffusion effects limiting substrate capture are ruled out.141 A 
similar hyperbolic KSVE pattern was seen for the deamination of D-histidine by D-
arginine dehydrogenase.142 Recently, a conformational change upon binding of NADPH 
and α-ketoglutarate by the GluDH from Aspergillus niger (An-GluDH) was demonstrated 
through x-ray crystallography.143 LeuDH and L-AmDH have a similar clamshell-like 
structure to An-GluDH, with two domains connected by a hinge region. The active site lies 
in the cleft between the two domains. Residues on both sides of the cleft have been 
identified as being important for either substrate binding or catalysis.114, 127 Upon binding 
of the substrate and cofactor, the two halves of An-GluDH move closer together by as much 
as 15 Å. Likely,  the equilibrium relationship between open and closed conformations of 
LeuDH is perturbed by an increase in viscosity and favors the closed conformation and 
thus the formation of products.144 
For LeuDH, a normal viscosity effect on the appkcat value was shown for reductive 
amination, meaning that increasing solvent viscosity decreases the overall turnover rate at 
substrate saturation. This effect indicates that overall turnover is partially limited by 
product release.121 The diffusion dependence is much stronger for reductive amination than 
for oxidative deamination. In the amination direction, a strong viscosity limitation on 
product release was not surprising given the large appkcat value of 330 s
-1
, as other enzymes 
with similar kcat values show similar results.
145-147 In the deamination direction at pH 9.5, 
 66 
the appkcat value is 20 s
-1 (data not shown); as a result, the viscosity effect in this direction 
is weaker. Interestingly, an inverse hyperbolic effect on the appkcat/KM,AmPent value was not 
observed for L-AmDH. Instead, a strong normal viscosity effect with slope of 0.75 was 
seen, despite the low appkcat/KM,AmPent value of 8.7 M
-1 s-1. This effect is the opposite of what 
was seen for the reductive amination direction and demonstrates that a viscosity effect 
drives an increase in concentration of the Michaelis complex in both directions. A 
decreased appkcat/KM,AmPent  in the deamination direction indicates slow substrate release 
while a decreasing  appkcat in the amination direction suggests slow product release; viscosity 
is likely affecting the same common step in each reaction direction as the substrate for the 
deamination direction is the product for the amination direction. 
The results described in the present study confirm key restrictions on reaction 
conditions which must considered to maximize reactor productivity. Increased viscosity 
should be avoided for the amination of ketones by L-AmDH, as a 4-fold increase in 
viscosity can lower the reaction rate by as much as 50% at saturating ketone concentration 
(Figure 2C). In a reactor setting, detrimental and beneficial KSVEs may be realized through 
the deliberate addition of glycerol to stabilize the biocatalyst148 and unintentionally through 
the introduction of kosmotropic anions such as formate or sulfate.149-150 As a result, 
engineers must optimize processes to balance stability and catalytic efficiently based on 
relative costs of catalyst and products. Additionally, it is important to avoid the strong 
product inhibition seen for L-AmDH to optimize amine production, especially, as 
competitive inhibition by 2-aminopentane on the already slow-binding 2-pentanone 
increases with conversion. Inhibition by NAD+ can be avoided by employing a large 
amount of the cofactor regeneration enzyme, which lowers [NAD+].  
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3.5 Conclusion 
Through initial rate, product inhibition, and KSVE experiments, we have 
demonstrated key differences between the kinetic mechanisms of L-AmDH and its parent 
enzyme, LeuDH. The 40-fold decrease in the appkcat value between the two enzymes can 
largely be explained by the much lower affinity for the ketone or amine substrate rather 
than affinity for ammonia. Kinetic viscosity effects elucidated the importance of an 
isomerization of the Michaelis complex for determining the rate of LeuDH catalysis, but 
the rate-limiting step is shifted for L-AmDH. A change in substrate binding order between 
the two enzymes was indicated by the differences in the fitted rate laws and inhibition 
patterns. An understanding of the kinetic properties of L-AmDH will enable its use in the 




CHAPTER 4. THE JOURNEY TOWARD CONTINUOUS 
MANUFACTURING OF CHIRAL AMINES 
4.1 Motivation and Introduction 
Of the four Aims which were initially set out for this thesis, continuous 
manufacturing of chiral amines with AmDHs was the most important. By 2016, the AmDH 
project in the Bommarius lab was already ten years old, with three previous graduate 
students and one lab manager involved in creating and improving the enzymes.2, 69, 103, 105, 
123, 151-152 Given the engineering background of the Bommarius group, it was important to 
move the use of AmDHs from cuvettes and test tubes into a scalable process which could 
produce tangible amounts of product. The primary deliverable of the entire thesis project 
from day one was a vial containing at least one gram of a pure (R)-amine. While CHAPTER 
5 presents the successful implementation of a continuous AmDH process, it does not tell 
most of the story of how we got there. CHAPTER 4 will give an overview of the ideas 
which were tried along the way but were ultimately not successful. As such, it will have a 
different format and style compared to the other chapters which surround it.  
4.2 The Enzyme Membrane Reactor 
4.2.1 Overview and Initial Setup 
The first attempt at continuous amine production utilized an enzyme membrane 
reactor (EMR), which was a 10 mL continuously stirred tank and would convert ketones 
to amines using soluble AmDH and FDH. The reactor was jacketed and fully watertight 
and was topped with a 10 kDa ultrafiltration membrane to retain the soluble enzymes while 
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allowing substrates and products to pass through freely. Because the products of AmDHs 
are chiral and the reactants achiral (except for the negligible concentration of 
NAD+/NADH), the plan was to measure conversion in the reactor continuously with a 
polarimeter equipped with a jacketed flow cell (Autopol® III, Rudolph Research 
Analytical, Hackettstown, NJ, USA). Temperature in the reactor and the polarimeter cell 
were controlled separately with circulating water baths. The enzyme membrane reactor 
used for AmDH catalysis was originally commissioned by the Bommarius lab for a study 
helmed by Dr. Thomas Rogers which sought to understand the thermal deactivation of 
TEM-1 β-Lactamase in a continuous, non-isothermal assay.153 The system worked quite 
well for Rogers, and was used again in the lab for a similar study by McDonald et al. in 
2018.154  
Figure 4-1 Photo of the continuous enzyme membrane reactor setup 
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4.2.2 Results and Challenges 
The continuous flow reaction system was set up as pictured in Figure 4-1. Conversion of 
multiple substrates (methyl-isobutyl ketone and acetophenone) with both L-AmDH and 
cFL1-AmDH was attempted with formate dehydrogenase for cofactor regeneration. Very 
slight changes in optical rotation were seen over time, but they were barely above the limit 
of detection of the polarimeter. For the previous work in the group with polarimetry, the 
molecules being studied were β-lactam antibiotics, which have specific optical rotation 
values that are between one and two orders of magnitude higher than those for any of the 
amines that the AmDHs can produce. The lack of sensitivity of the polarimeter toward 
detecting the amines produced in the reaction meant that polarimetry could not be used to 
measure conversion moving forward. 
Ultimately, the use of the EMR was abandoned due to stability problems with the amine 
dehydrogenases. Both AmDHs used in the study are not stable enough to be used 
continuously in solution overnight and tend to aggregate. Multiple days of operation were 
desired for a truly continuous process, the aggregation problem ended up being serious 
enough that other options were needed. 
4.3 Immobilization Onto Immobeads in a Packed Bed Reactor 
4.3.1 Rationale  
After the failure of the initial experiments with the EMR, it was clear that 
immobilization would be necessary to prevent aggregation and subsequent deactivation of 
the enzymes. The EMR is unsuitable for biocatalysts immobilized onto solid supports 
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because the action of the magnetic stir bar will grind any porous polymer over time and 
eventually deactivate the catalyst. As a result, a new platform for immobilizing the 
enzymes onto macroporous beads and subsequently packing into a tubular reactor was 
explored. In February of 2019, a screening kit containing twelve different macroporous 
resins marketed especially for enzyme immobilization called Immobeads® was acquired 
(Chiralvision B.V., Den Hoorn, the Netherlands). The types of binding chemistries offered 
in the kit are shown in Figure 4-2. Three of the beads use covalent immobilization via ring 
opening reactions between epoxide groups on the bead surface and lysine residues on the 
protein surface. A further four beads use adsorption interactions, including polar and 
nonpolar adsorption. The final five resins are ion exchange resins, which include one cation 
exchange and four amine anion exchange resins with primary, secondary, tertiary amine 
and a quaternary ammonium options. Depending on the protein of interest and its surface 
chemistry, different binding chemistries would be most effective at binding and retaining 
enzyme. As such, it was useful to try a wide range of options, rather than assuming a single 
chemistry would work. Importantly, all of the resins in the kit bind nonspecifically, so it is 
important to purify proteins prior to immobilization.  
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4.3.2 Initial Immobilization Screening 
The immobilization procedure for all 12 beads in the kit is straightforward: purified 
protein at a known concentration is incubated with a defined mass of the beads overnight 
without shaking at 4 °C. Following the incubation time, the beads are filtered, and washed 
with water to remove traces of unbound enzyme. Afterward, the beads are ready to be 
screened for activity. The degree of binding to the beads can be quantified by measuring 
the concentration of protein in the supernatant after filtering and comparing to the 
concentration of enzyme in solution prior to immobilization. Immobilization of both cFL1-
AmDH103 and the formate dehydrogenase from Candida boidinii (FDH) were screened 
Figure 4-2 Promotional image from ChiralVision outlining their available enzyme 
binding chemistries 
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against all twelve bead types, to assess their binding and immobilized activity, the results 
can be seen in Table 4-1. The degree of binding is defined as the residual enzyme 
concentration after binding divided by the initial enzyme concentration. 
Table 4-1 Degree of binding of cFL1-AmDH and FDH to various enzyme 
immobilization beads 
 
 For the binding screen shown in Table 4-1, the initial concentrations of cFL1-
AmDH and FDH were 2.42 mg/mL and 1.24 mg/mL, respectively as measured by the 
Bradford Assay.115 The limit of detection of the Bradford assay kit used for this study is 
about 0.1 mg/mL, which is why quantification of binding efficiency was limited to a range 
above a certain percentage. Of the twelve beads in the kit, only five showed complete 
binding of both enzymes, this group included two of the covalent beads, two adsorption 
beads, and one anionic exchange bead. 
cFL1-AmDH FDH
covalent 1 apolar epoxide/butyl < 96% < 92%
covalent 2 polar epoxide < 96% < 92%
covalent 3 polar epoxide < 96% 87.9%
adsorption 1 apolar phenyl 78.9% 80.7%
adsorption 2 apolar carboxylic ester 94.3% < 92%
adsorption 3 apolar octadecyl < 96% < 92%
adsorption 4 polar styrene/methyl 71.3% 76.7%
cationic 1 strong sulphonic 31.6% 34.4%
anionic 1 apolar primary amine < 96% < 92%
anionic 2 weak tertiary amine 82.7% 68.5%
anionic 3 weak quaternary ammonia 88.3% 52.7%







 After the binding screen, the immobilized enzymes were screened for activity by 
flowing a solution containing reaction substrates through a gravity flow column containing 
the beads and measuring absorbance before and after. For AmDH, activity toward 50 mM 
2-hexanone with 200 μM NADH in 1M NH4COOH pH 8.5 was measured and for FDH the 
reaction contained 400 μM in 1M NH4COOH at pH 8.5. Absorbance values of repeated 
flow-throughs of the same 1 mL of reaction solution were measured to estimate the reaction 
rate. Both AmDH and FDH were active on the two covalent immobilization resins, but at 
levels at least 100x slower than the expected rates in free solution, which is too much of an 
activity decrease to be acceptable. The two adsorption beads exhibited significant leaching 
of enzyme almost immediately when exposed to the reaction buffer, so they were also 
removed from consideration. The anion exchange resin seemed to show initial promise in 
the 1 mL reactions, with initial activity and no detectable leaching of either enzymes at pH 
8.5. As the pH was increased to 9.5, some enzyme was removed from the resin, likely due 
to deprotonation of the primary amine groups on the bead surface. Despite the leaching at 
pH 8.5 the results were promising, and the beads were tested for their suitability in 
continuous flow mode. 
4.3.3 Continuous amine Production Results 
The anion exchange resin with co-immobilized cFL1-AmDH and FDH (4 mg of 
each) was packed into a 1 mL disposable flow cartridge (EB-Ctg1-5, Agarose Bead 
Technologies, Miami, FL, USA) and incorporated into a continuous flow setup with a 
recycle loop (see 4.5 for a discussion of the recycle system). To accomplish the binding, 
empty resin was first packed into the reactor, then a solution containing both enzymes in 
PBS was continuously circulated through the resin with a peristaltic pump until the 
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concentration of enzyme in the bulk solution was negligible. After binding, the resin was 
rinsed with fresh PBS, and no enzyme was present in the runoff. An image of the reactor 
cartridge is shown in Figure 4-3. At the time of their use, these cartridges appeared to be 
the best option for this reactor setup. However, they had two large disadvantages: they do 
not have an adjustable volume, and they can only be used once because the tabs that keep 
the reactor sealed cannot be undone without damage. 
The feed solution contained 20 mM acetophenone, 0.5 M NH4COOH, 1.5 M NH4Cl, 
1 mM NAD+ and was adjusted to a pH value of 8.5. Temperature of the reactor was held 
constant with the use of a large water bath and a sous vide circulating heater. A photo of 
Figure 4-3 Rector cartridge packed with 
Immobeads® 
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the setup is shown in Figure 4-4. Feed solution was fed at a rate of 150 μL/min and the 
recycle flow rate was set at 3000 μL/min. Samples were taken at regular intervals over the 
course of five days. Flow through the reactor was unstable, with sudden partial clogging 
events which would eventually become unblocked. The experiment eventually ended when 
a clog caused the peristaltic tubing to burst off its barbed fitting. Examination of the 
samples taken from the first hours of the experiment identified large amounts of protein in 
the outlet. The level of enzyme leaching in prior batch experiments was likely not large 
enough to be detected, but the continuous flow and high recycle ratio likely contributed to 
the leaching. Any amount of significant leaching is unacceptable for continuous operation, 
Figure 4-4 Photo of the first packed bed reactor setup with AmDH and FDH. The 
reactor located inside the red plastic bag. 
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so the use of these beads was immediately abandoned. Due to difficulties with HPLC 
method development, the conversion for this continuous trial was never measured, but it is 
assumed that conversion was very low. 
4.4 Immobilization onto Immobeads® Modified with Leucine Zippers 
4.4.1 Leucine Zipper Binding Scheme 
After all the 12 binding chemistries from ChiralVision were ruled out, a different 
strategy was developed in collaboration with Adam Caparco to utilize the covalent binding 
chemistry of the Immobeads® with the leucine zipper immobilization technology 
developed by the Champion group at Georgia Tech. Leucine zippers, originally found in 
DNA binding protein, are protein structures consisting of  pairs of alpha helices, one rich 
in glutamate (ZE) and another rich in arginine (ZR), which form very tight and specific 
heterodimers.98-99 The ZE zipper was attached to both cFL1-AmDH and cb-FDH using an 
engineered linker, generating AmDH-ZE and FDH-ZE. In a separate peptide, two copies 
of the ZR zipper are attached by an unstructured linker to form construct called ZRC10ZR. 
Figure 4-5 Covalent binding of ZRC10ZR to Immobeads® followed by noncovalent 
binding of AmDH-ZE via leucine zipper interactions 
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If ZRC10ZR is immobilized onto a solid support, then the ZE tags attached the enzymes will 
bind tightly, allowing for noncovalent, but very strong immobilization. It has been shown 
previously by Caparco et al. that enzymes immobilized with this chemistry retained their 
structure and activity. The sequences of the enzymes involved, ZRC10ZR, and methods for 
their expression and purification have been published previously.98-99 Importantly, the 
linker sequence of ZRC10ZR contains exactly one lysine residue, which meant it could be 
covalently immobilized to the one of the Immobeads® (IB-COV2) using epoxide ring 
opening chemistry. A general schematic of the binding strategy is shown in Figure 4-5.  
4.4.2 Immobilization Results 
Covalent conjugation of ZRC10ZR to IB-COV2 was accomplished by incubating a 
solution containing the pure protein in PBS overnight rotating in a cold room at 4 °C. After 
washing off excess unbound protein, the remaining epoxide groups which had not reacted 
with protein were quenched with 250 mM methylamine. This was done to prevent 
unwanted covalent binding, and deactivation, of AmDH and FDH to the beads. After 
quenching, the beads were washed again with PBS, and then incubated with a PBS solution 
containing AmDH-ZE, FDH-ZE, or both. As expected, ZRC10ZR was readily able to bind 
to the bead, as measured by absorbance at 280 nm before and after incubation. 
Additionally, AmDH-ZE and FDH-ZE were both able to bind to the beads after 
conjugation with ZRC10ZR and quenching. Finally, both enzymes retained their activity 
when immobilized separately. The precise specific activity of the enzymes compared to the 
values in free solution was not measured. After incubation of the beads for 24 hours in 2 
M NH4COOH, no protein was detectable by the Bradford assay in the aqueous phase, 
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which indicated the leucine zipper immobilization did not suffer the same leaching problem 
as the anion exchange binding chemistry. 
4.4.3 Continuous Amine Production Results  
The leucine zipper immobilization strategy did not end up being successful. While 
two continuous reactor assays were attempted, neither produced measurable conversion. 
One possible reason for this is channelling effects within the beads due to the reaction 
solution. Additionally, expression of AmDH-ZE and FDH-ZE at the time was very 
difficult, with yields as low as 10 mg of protein per liter of culture. Further development 
of the AmDH-ZE based reactor stopped when the BioRad Nuvia IMAC resin showed 
positive results (see CHAPTER 5). Use of the Nuvia resin allowed for the use of the 
standard 6xHis-tagged AmDH and FDH, which have much higher expression levels. 
4.5 The Packed Bed Recycle Reactor (PBRR) 
The successful packed bed flow reactor described in CHAPTER 5 was originally 
intended to include a recycle stream that would return a portion of the reactor outlet directly 
back to the inlet. It was assumed that the recycle stream would increase the mean residence 
time of the reactor without decreasing the inlet flow rate, thus increasing productivity. The 
reactor configuration was inspired by the circulating batch or fed-batch plug flow reactors 
which have been used periodically for enzyme-catalyzed reactions.155-158 These batch 
systems consist of a packed bed tubular reactor and a stirred reservoir. Fluid is continuously 
pumped from the reservoir, through the packed bed, and back into the reservoir. A second 
potential benefit of a rapid recycle stream is that the real flow rate in the reactor is much 
faster for a given inlet flow rate compared to a single-pass reactor. An increase in the flow 
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rate will increase the external mass transfer coefficient, kLa, and would potentially alleviate 
any external mass transfer limitations in the system. See 5.5.4 for a more detailed 
discussion of external mass transfer limitations in packed bed reactors. The PBRR setup 
went through multiple iterations with improvements to the reactor, sample collection, air 
removal, and flow characterization along the way. 
4.5.1 System Setup 
The final setup of the PBRR is shown in Figure 4-6. Flow into the system comes 
either from the substrate inlet bottle or tracer inlet tube. A selection valve (V-100L, Idex 
Health & Science, Oak Harbor, WA, USA) allows for rapid switching between inlets. A 
peristaltic pump (IsmatecTM IPC-4, Cole-Parmer, Vernon Hills, IL, USA) with 1.30 mm 
ID 2-stop santoprene tubing (Precision Glassblowing, Centennial, CO, USA) pumps fluid 
first through a bubble trap (OmnifitTM 006BT, Diba Industries, Danbury, CT, USA). The 
fluid then flows through 1.6 meters of 1/16 inch O.D. stainless steel tubing followed by the 
Figure 4-6 Photo of the final packed bed recycle reactor setup 
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reactor (OmnifitTM EZ SolventPlusTM 10mm x 100 mm chromatography column with one 
adjustable endpiece, Diba Industries, Danbury, CT, USA). The steel tubing and reactor are 
both submerged in a water bath with the temperature controlled by a thermal immersion 
circulator (PrecisionTM Cooker, Anova Culinary, San Francisco, CA, USA). The fluid from 
the reactor outlet is split into two streams at a steel T-shaped union. The outlet stream flows 
through a digital flow meter (SLI-1000, Sensirion AG, Stäfa, Switzerland) and then into 
an automated fraction collector (BioFracTM Fraction Collector, Bio-Rad Laboratories, 
Hercules, CA, USA). From the outlet splitter, the recycle stream is pulled through a digital 
flow meter (SLI-2000, Sensirion AG, Stäfa, Switzerland) by a second peristaltic pump 
(IsmatecTM REGLO Digital MS-4/12, Cole-Parmer, Vernon Hills, IL, USA) equipped with 
tubing with the same composition and internal diameter as the feed pump. The recycle 
stream then travels from recycle pump to a T-junction located directly downstream of the 
feed pump, where the two streams are mixed and fed to the reactor. 
4.5.2 Residence Time Distributions in the PBRR 
Residence time distributions at various flow rates and recycle ratios were collected for the 
PBRR system using the same methods described in 5.3.10.  Four RTDs all collected at the 
same inlet flow rate (344 µL/min), but different values of R, the recycle ratio are shown in 
Figure 4-7. At small recycle ratios, individual peaks are baseline-separated in the RTD. 
Each peak in the RTD is a single pass through the reactor loop. As the recycle ratio 
increases, the separation between peaks in the RTD decreases. As the recycle ratio 
increases beyond the 5.9 value shown in the figure, the RTD approaches an ideal CSTR 
with a delay time. The single pass residence time was 15.8 minutes, while the residence 
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time for recycle ratios of 1.2, 3.6, and 5.9 were 20.9 minutes, 20.8 minutes, and 18.8 
minutes, respectively. 
4.5.3 Conversion Results and Why it Would Not Have Worked 
In parallel to the work on characterizing the flow behavior in the PBRR, work was 
ongoing to develop an enzyme immobilization strategy and product quantification strategy 
which would enable continuous operation. The assumptions about the possible benefits of 
an increased recycle ratio were not really put to the test until all the other pieces were in 
place, which did not happen until January 2020. Once the first continuous assays were 
performed, it was found that running the reaction at a recycle ratio of 10 resulted in a 
decrease in conversion of 20% compared to a single pass at the same inlet flow rate (data 
Figure 4-7 Residence time distributions in the PBRR for various recycle ratios. For 
all residence time distributions in this plot, inlet the inlet flow rate was fixed at 344 µL/min 
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not shown). Once this result was obtained, it was quickly decided to remove the recycle 
stream and stop working on characterizing its performance. 
Ultimately, the recycle ratio for this type of reactor system has absolutely no impact on 
the mean residence time in the reactor, despite the apparent increases in τ indicated by the 
collected residence time distributions. The proof of this is described below, and is adapted 
from a 1967 paper by David Rippin on using a recycle reactor to model incomplete 
mixing.159 
 Consider a system as shown in Figure 4-8 which has inlet flow rate Q, reactor 
volume V, and recycle ratio R. For the purposes of this derivation it is assumed that the 
inlet, outlet, and recycle lines have zero volume. The flow rate in the recycle stream is 
equal to RQ, and the flow rate through the reactor is equal to (1+R)Q. Now, a pulse with a 
differential duration is introduced to the inlet. It will spend an amount of time in τ1 in the 
reactor before it reaches the outlet where τ1 = V / (1 + R)Q. At the outlet a fraction f1 of the 
initial tracer leaves the reactor, where f1 = 1 / (1+R), and the remaining fraction, R / (1+R), 
is recycled. The fraction of the tracer that is left travels through the reactor again and 
reaches the outlet, where a fraction f2 of the remaining tracer exits, where f2 is given by (9). 













The fraction of the tracer which leaves after two passes spent a total amount of time τ2 in 
the reactor, where τ2 = 2V / (1 + R)Q. This process repeats continuously, with more and 
more of the tracer leaving after each pass. The total residence time of pass i, is τi, where τi 
= iV / (1 + R)Q. The fraction, fi, of the original tracer which exits the reactor after pass i is 











The mean residence time of the entire tracer pulse, τ, is thus given by (11).  
 
















This sum, when evaluated out to infinity, reduces to τ = V / Q, meaning the mean residence 
time is independent of the recycle ratio.  
 Unlike the ideal PBRR from the above derivation, the recycle loop in the real PBRR 
had a nonzero volume. The measured increases in mean residence time due to elevated 
recycle ratio thus represented the time that the tracer spent in the recycle loops between 
passes, not extra time in the reactor. Because the enzyme is immobilized, the time spent in 
the recycle loop is non-productive and should be ignored when considering reactor 
performance. At high recycle ratios, the PBRR acted as a CSTR with a certain dead volume. 
Despite the unproductive dead volume, effective reactor volume of the simulated CSTR is 
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the same as the packed bed volume. In the PBRR, conversion was 20% lower when the 
reactor was operated at a high recycle ratio compared to the level of conversion when the 
reactor was operated in single-pass mode at the same inlet flow rate. The results of the 
recycle experiment show that for an AmDH reaction at these reactor conditions, a CSTR 
will give a lower conversion than a PFR of the same volume. This is consistent with the 
expected behavior for product inhibition-limited reactions taught in introductory reactor 
design courses.160 There are a couple of examples in the literature of a PBRR being used 
with the intention of enhancing enzymatic reactions. In one case, increasing the recycle 
ratio did not negatively impact reaction kinetics. The authors spoke of the lack of 
significant product inhibition, as the reason high amounts of product recycling would not 
harm reaction rates.161 In another study, the use of a PBRR actually enhanced conversion 
for an autocatalytic protease-driven process.162  
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CHAPTER 5. CONTINUOUS PRODUCTION OF CHIRAL 
AMINES IN A PACKED BED REACTOR 
5.1 Introduction 
Amine dehydrogenases (AmDHs), first engineered in 2012.2 are a family of enzymes 
which catalyze the reductive amination of prochiral ketones to form chiral amines. Chiral 
amine functional groups can be found in many of the current top selling small molecule 
drugs like sitagliptin (Januvia®), oseltamivir phosphate (Tamiflu®), and dolutegravir 
(Tivicay®)7 and their efficient production is an important challenge in the pharmaceutical 
industry. The chiral purity of many active pharmaceutical ingredients (APIs) must be 
greater than 99% to ensure efficacy or avoid adverse side effects.163 The naturally high 
enantioselectivity of enzyme catalysts, among other benefits, have made them increasingly 
interesting to the industry and academics82, 100, 164-165 for the production of chiral APIs 
including amines. 
The application of continuous flow chemistry to biocatalysis has also been increasingly 
attractive in the pharmaceutical and fine chemical industries.166 The current paradigm for 
biocatalysis in most of the pharmaceutical industry calls for large stirred batch reactors into 
which enzyme, either soluble or immobilized, is added as a reagent. After the reaction is 
complete, processing steps are required to remove the enzyme. Continuous flow reactions 
with immobilized enzymes combine the reaction and biocatalyst separation steps into a 
single unit operation. The operational lifespan of the enzyme, known as the total turnover 
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number (TTN), can also be significantly higher in flow reactors due to the stabilizing 
effects of immobilization94 and the ease of enzyme reuse compared to batch reactors. 
The family of AmDHs has been under continuous development by groups around the 
world since their first publication eight years ago. The first examples were the leucine 
amine dehydrogenase (L-AmDH) engineered from the natural leucine dehydrogenase 
(LeuDH) from Geobacillus stearothermophilus2 and the phenylalanine amine 
dehydrogenase (F-AmDH) engineered from the natural phenylalanine dehydrogenase 
(PheDH) from Bacillus badius.69 For both L-AmDH and F-AmDH, homologous residues 
in the active site responsible for binding the carboxylic acid group on the natural amino 
acid substrate were mutated to instead promote binding to methyl ketones. A similar 
strategy has been employed by other groups to generate AmDHs based on other PheDH 
and LeuDH scaffolds.70, 74, 104 Recently the Mutti group were able to generate an AmDH 
from the ε-deaminating L-lysine dehydrogenase from Geobacillus stearothermophilus 
which showed activity toward substrates not as easily accessible with the previous 
engineered AmDHs.76 Work has also been done through high-throughput screening and 
metagenomic mining to identify naturally occurring AmDHs.78, 106  
Figure 5-1 Reductive amination of 5-methyl-2-hexanone with cofactor regeneration 
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There is a growing interest in the pharmaceutical industry to replace the nearly 
ubiquitous batch reactors with continuous flow chemistry where possible.167 Continuous 
processing can offer key advantages over batch reactors in terms of reducing 
manufacturing time, plant footprint, and waste. Since 2013, the U.S. Food and Drug 
administration has been encouraging pharmaceutical companies to pursue continuous 
processes.168 Continuous processing is especially attractive for heterogeneous catalysis, as 
product separation from the solid phase occurs simultaneously with reaction. Continuous 
flow processes are also easier to monitor and control, as they tend to operate at steady state 
rather than in a transient mode. Ease of control over reaction conditions can yield tighter 
control over product purity. For enzymes specifically, continuous processing can alleviate 
product inhibitions due to the in-situ removal of products. Additionally, the total turnover 
numbers of enzymes in continuous processes tend to be higher than for batch reactions, 
leading to more efficient use of resources.166 
The primary goal of the reported work was to demonstrate a stable application of 
continuous flow chemistry to the production of chiral amines with an AmDH. The chimeric 
amine dehydrogenase cFL1-AmDH,103 which will subsequently be referred to here as 
AmDH, was chosen for its thermostability and high expression levels. AmDH, along with 
the formate dehydrogenase (FDH) from Candida boidinii, was used to convert 5-methyl-
2-hexanone (5M2H) to (R)-5-methyl-2-aminohexane with ammonium formate and NADH 
as co-substrates (see Figure 5-1). Initially, the biocatalysts in solution were fed into a 
continuously stirred enzyme membrane reactor like the one employed by Rogers et al. to 
study the deactivation of TEM-1 beta-lactamase.153 Unfortunately, the tendency of AmDH 
to aggregate in solution under reaction conditions rendered continuous soluble operation 
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impossible. Our focus then shifted toward co-immobilizing AmDH and FDH onto a solid 
support for use in a packed bed reactor (PBR), which showed much greater promise. 
5.2 Enzyme immobilization 
The immobilization support for AmDH and FDH needed to be robust under reaction 
conditions, have tight binding without significant leaching, be amenable to packing into a 
flow column with good flow properties, and be readily available. Multiple groups in the 
past 5 years have explored co-immobilization of AmDHs with FDH and with other 
enzymes like ω-transaminases and alcohol dehydrogenases.88, 97-98, 107 While the reported 
immobilization strategies met some of the listed criteria, none seemed to meet all of them. 
In this work, all twelve of the Immobead® enzyme carriers offered commercially by 
ChiralVision, which included 10 different binding chemistries, were screened for their 
effectiveness. Despite promising binding efficiency on a few of the beads, the physical 
properties of the Immobeads yielded significant channeling effects when tightly packed 
into a column which rendered them unsuitable. 
Ultimately the immobilization strategy chosen for this study was to use a commercial 
immobilized metal affinity chromatography (IMAC) resin from Bio-Rad called Nuvia 
IMAC. This resin is charged with divalent nickel ions which have been immobilized to the 
49 µm acrylamido polymer beads with covalently bound nitriloacetic acid (NTA). A 
polyhistidine (6xHis) tag is recombinantly expressed at either the C- or N- terminus of a 
target enzyme, and under the right conditions this 6xHis tag tightly chelates the 
immobilized nickel ion.169 Once chelated to the nickel, the 6xHis-tagged proteins are 
tightly bound, but still retain their folded structure and activity. While IMAC resins have 
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traditionally been used for protein purification rather than enzyme immobilization, Merck 
and Co. recently demonstrated the use of Nuvia IMAC for the production-scale 
immobilization of multiple enzymes in the production of their Phase 3 HIV drug islatravir 
(MK-8591).170 EnginZyme in Sweden has also developed a range of IMAC resins for 
enzyme immobilization with slightly different metal ion immobilization chemistry.  The 
Turner group demonstrated the use of EziG Amber, which employs immobilized Fe3+ 
rather than Ni2+, for use with co-immobilized AmDH and FDH in a packed bed flow 
reactor.96  The authors in that study reported 68% conversion of a 10 mM inlet stream of 
4-fluorophenylacetone to form 4-fluoroamphetamine and a volumetric productivity over 
300 g/L/day. However, this level of productivity was only stable for a reported 3 hours 
before rapid deactivation of the catalyst. In the present study, we report the successful 
application of the Nuvia IMAC resin to immobilize AmDH and FDH in a flow reactor with 
productivity values similar to those found for the EziG immobilization, but with an 
apparent half-life exceeding five days. 
5.3 Materials and Methods 
5.3.1 Sources of Raw Materials 
Materials used for enzyme expression and purification, as well as product quantification 
with benzoyl chloride were published previously.79 Additional materials are listed below. 
Ni-charged Nuvia® IMAC resin (Bio-Rad Laboratories, Hercules, CA, USA), 5-methyl-
2-hexanone 99% (Alfa Aesar, Ward Hill, MA, USA), 5-methyl-2-aminohexane 98% 
(Santa Cruz Biotechnology, Dallas, TX, USA)  
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5.3.2 Buffers Used for Expression, Immobilization and Reaction 
Binding Buffer: 1X phosphate-buffered saline (PBS), 300 mM additional NaCl, 
10 mM imidazole; Wash Buffer 1: 1X PBS, 300 mM additional NaCl, 20 mM imidazole; 
Wash Buffer 2: 1X PBS, 300 mM additional NaCl, 40 mM imidazole; Elution Buffer: 
1X PBS, 300 mM additional NaCl, 250 mM imidazole; Reaction Buffer: 2M ammonium 
formate (NH4COOH) adjusted to pH 8.5 with 2M NH4OH, 20 mM 5-methyl-2-hexanone, 
variable concentration of NAD+ between 0.1 and 4 mM; Autoinduction Media: 1X PBS, 
5 g/L NaCl, 20 g/L tryptone broth, 5 g/L yeast extract. This solution is autoclaved in 500 
mL batches in 2.8 L baffled shake flasks. After it has cooled, a 50 mL mixture containing 
12.5 mg kanamycin, 6 mL glycerol, 0.5 g glucose, and 2 g lactose is filtered through a 0.22 
μm syringe filter into the baffled flask. 
5.3.3 Enzyme Expression 
Engineered cFL1-AmDH103 and wild-type cb-FDH are expressed separately, but 
with identical procedures. The gene is stored in the pet28a vector with NdeI and XhoI 
restriction sites, giving the enzyme an N-terminal 6xHis-tag. After transformation into E. 
coli BL21(DE3) cells, frozen cell stocks are stored at -80 °C in 10% DMSO. 5 mL 
(standard LB media with 25 mg/L kanamycin) overnight cultures are seeded from the 
frozen stock and allowed to grow for 16 hours shaking at 37 °C and 250 RPM. The 5 mL 
starter culture is used to seed 500 mL of autoinduction media. After incubation for 24 hours 
at room temperature in a 125 RPM orbital shaker, cells are spun down at 2,800 g for 35 
minutes. The supernatant is removed, and cell pellets stored at -20 °C or -80 °C for short-
term or long-term storage, respectively.  
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5.3.4 Enzyme Purification 
Frozen cell pellets resuspended are in an amount of binding buffer based on the size 
of the expression culture which produced the pellet. A pellet from a 500 mL expression is 
resuspended in 40 mL of binding buffer. After resuspension, the mixture is split into 20 
mL aliquots and sonicated to break open the cells. After cell lysis, the crude lysate is 
centrifuged at 12,000 g for 40 minutes at 4 °C. Each 20 mL aliquot of clarified lysate is 
incubated in a separate gravity filtration column for 1 hour at room temperature with 2 mL 
of Bio-Rad Nuvia IMAC resin which had been previously washed with 30 mL of DI water 
and 40 mL of binding buffer. After incubation, the column is drained, and subsequent 
washes are completed first with 10 mL of wash buffer 1 followed by 10 mL of wash buffer 
2. After washing, elution buffer is added in 2.5 mL increments and is collected after 
incubation at room temperature for 5 minutes. Subsequent fractions are collected until the 
protein concentration in the outlet is less than 1 mg/mL as measured by the Bradford 
assay115. Elution fractions are buffer exchanged back into the binding buffer using a PD10 
desalting column (GE Lifesciences, Chicago, USA) with standard procedures. After 
desalting, pure protein solutions are stored at 4 °C until needed. 
5.3.5 Enzyme Immobilization 
Empty Nuvia IMAC Ni-NTA resin is stored as a 66% slurry in 20% ethanol. For 
immobilization, the desired quantity of resin was first washed in a gravity filtration column 
with 10 bed volumes of deionized water, followed by 10 column volumes of binding buffer. 
With the column equilibrated in binding buffer, enzyme can be introduced to the resin in 
form either of purified protein or clarified lysate. After incubation overnight on a rotary 
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mixer (Roto-MiniTM Rotator Series R2020, Benchmark Scientific Inc, Sayreville, NJ, 
USA), the resin is washed with 10 bed volumes of wash buffer 1, followed by 10 bed 
volumes of 2.0 M NH4COOH/NH4OH at pH 8.5. The resin is now ready to be packed into 
a column or transferred to a batch reaction. 
5.3.6 Binding Capacity Determination 
The binding capacity of the Nuvia IMAC resin was determined for both AmDH 
and FDH separately in a continuous flow binding experiment. The reactor system was set 
up as shown in Figure 5-2. Stock solutions of AmDH (100 mL, 0.72 mg/mL) and FDH 
(100 mL, 0.468 mg/mL) in Binding Buffer were prepared and kept at 4 °C or on ice for the 
duration of the experiment. For each enzyme, 0.666 mL (settled bed) of fresh resin were 
packed into the reactor column (OmnifitTM EZ SolventPlusTM 10mm x 100 mm 
chromatography column with one adjustable endpiece, Diba Industries, Danbury, CT, 
USA) and the column was attached into the flow system. After equilibration of the column 
with at least 20 mL of binding buffer, the inlet was switched to the enzyme solution, which 
flowed slowly at 0.168 mL/min through the column. 384 fractions of 230 µL were collected 
into four UV-transparent 96-well plates using a programmable fraction collector. The 
change in absorbance at 280 nm between the enzyme stock solution and the reactor outlet 
could then be used to determine the amount of enzyme which had bound to the enzyme out 
of each mL that flowed through the resin. For both enzymes, the amount of stock solution 
was not large enough to fully saturate the resin, so the remaining portion of the binding 
isotherm was extrapolated. Integration of the binding curves (see Figure 5-4) yields the 
specific binding capacities of the resin for each enzyme. 
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5.3.7 AmDH to FDH Binding Ratio Optimization 
Based on the binding capacities obtained from 5.3.6, and the assumption that the 
two enzymes have the same rate of binding, the amount of AmDH and FDH needed to 
saturate 0.2 mL of Nuvia IMAC resin plus 25% was calculated for 5 mass ratios. The ratios 
and masses of each enzyme required for each ratio are listed in Table 5-1. For each ratio, 
0.2 mL of resin are prepared as described in 5.3.5, and purified enzyme is prepared as 
described in 5.3.4. The required amounts of each enzyme (in binding buffer) are mixed 
together in a 15 mL conical tube and diluted up to 15 mL with binding buffer. The enzyme 
mixtures are then used to slurry transfer the resin from the gravity columns to the conical 
tubes. After incubation overnight, rotating at 20 RPM at room temperature, the 5 
immobilized biocatalyst samples are washed with 20 bed volumes of 2.0 M 
NH4COOH/NH4OH at pH 8.5 and then transferred to 50 mL conical tubes, each containing 
50 mL of reaction buffer with 1 mM NAD+. The batch reactions proceed for 21 hours at 
room temperature and rotating at 20 rpm, with samples taken at selected timepoints by 
stopping the rotisserie mixer and allowing the resin to settle for 5 minutes before collecting 
100 μL of supernatant, which is stored at 4 °C until all timepoints have been collected. 
Quantification of conversion is described in 5.3.11. 
5.3.8 Continuous Flow Reactor System Setup  
A representative schematic of the continuous flow reactor used in the present study 
can be found in Figure 5-2. 
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Flow into the system comes either from the substrate feed bottle or tracer inlet tube. 
A selection valve (V-100L, Idex Health & Science, Oak Harbor, WA, USA) allows for 
rapid switching between inlets. A peristaltic pump (IsmatecTM IPC-4, Cole-Parmer, Vernon 
Hills, IL, USA) with 1.30 mm ID 2-stop santoprene tubing (Precision Glassblowing, 
Centennial, CO, USA) pumps fluid first through a bubble trap (OmnifitTM 006BT, Diba 
Industries, Danbury, CT, USA). The fluid then flows through 1.6 meters of 1/16 inch O.D. 
stainless steel tubing followed by the reactor (OmnifitTM EZ SolventPlusTM 10mm x 100 
mm chromatography column with one adjustable endpiece, Diba Industries, Danbury, CT, 
USA). The steel tubing and reactor are both submerged in a water bath with the temperature 
controlled by a thermal immersion circulator (PrecisionTM Cooker, Anova Culinary, San 
Francisco, CA, USA). Once through the reactor, fluid flows through a digital flow meter 
(SLI-1000, Sensirion AG, Stäfa, Switzerland) and finally into an automated fraction 
collector (BioFracTM Fraction Collector, Bio-Rad Laboratories, Hercules, CA, USA). 
5.3.9 Flow Meter Calibration 
The flow meter used in this study must be calibrated for each solution it is used for. 
At various pump speed settings, the desired fluid is pumped through the flow meter, and is 
collected for precise amounts of time into pre-tared tubes with the fraction collector. The 
mass of fluid in each tube is converted to a volumetric flow rate by dividing by the 
collection time and by the density as measured by an Anton Parr Density Meter DMA35. 
Figure 5-2 Block flow diagram of the continuous flow packed bed reactor system 
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Comparison of the real flow rate to averaged flow rate as measured by the flow meter is 
used to produce a pump curve and calibration curve (not shown). 
5.3.10 Residence Time Distributions 
Flow through the reactor was characterized through the measurement of the 
residence time distribution at various flow rates. The reaction system is set up as described 
in 5.3.8 with 1X PBS in the substrate feed bottle and 20 mM NADH in the tracer inlet tube. 
The reactor column was packed with 2 mL (settled bed) of empty Nuvia IMAC resin. The 
fraction collector was configured to collect with the required sampling time collect 200 μL 
samples into the wells of two 96-well flat bottom polystyrene plates. After purging of the 
tracer inlet line and subsequent equilibration with 1X PBS, an RTD experiment was 
commenced by simultaneously starting the fraction collector sequence and rapidly 
switching the selection valve to allow for the flow of the tracer solution into the reactor for 
one second, then rapidly switching back to PBS. Once 186 fractions were collected into 
the two plates, the absorbance of each well at 340 nm was measured in using BioTek 
Synergy H4 Hybrid Reader (BioTek Instruments Inc., Winooski, VT). Absorbance values 
were normalized by dividing by the average absorbance of the process fluid at steady state. 
For each experiment, the residence time distribution, E(t), was obtained from the 









 The mean residence time between the tracer inlet valve and the fraction collector 
outlet, τsys, is obtained from the E(t) by (13).  
 




Once the mean residence time has been determined, the residence time distribution 






 The dimensionless time, θ, is defined as t/τsys. Finally, the variance, σ
2 of the residence 
time distribution is given by (15). 
 




The one-dimensional dispersion model with Dankwerts boundary conditions was 
utilized to estimate the Peclet number (Pe) for each of the collected RTDs by solving (16) 









(1 − 𝑒−𝑃𝑒) (16) 
5.3.11 Conversion Determination With HPLC 
Conversion in the reactor was determined by direct measurement 5-methyl-2-
aminohexane concentration after derivatization with benzoyl chloride. The procedures for 
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derivatization and quantification of primary amines with reverse-phase HPLC have been 
described previously.79  
5.4 Results 
5.4.1 Enzyme Leaching Under Reaction Conditions 
It had been previously speculated that high concentrations of ammonia/ammonium 
in solution could lead to elution of bound proteins from Ni-NTA resins. To test this 
hypothesis, AmDH (11.3 mg) and FDH (5.1 mg) were each immobilized separately onto 
0.25 mL of resin. After incubation of the samples at room temperature in 10 mL of a 2.5 
M NH4COOH solution at pH 8.5 for two hours, no protein was detectable by the Bradford 
assay in the bulk solution for either enzyme. The absence of detectable enzyme leaching in 
the short term indicated the resin was suitable for further testing. 
5.4.2 Enzymatic Activity and Stability in Reaction Conditions 
The two samples of separately immobilized biocatalyst from 5.4.1 were combined 
and employed in a 10 mL batch conversion of 20 mM 5M2H for 24 hours at room 
temperature. The immobilized enzyme was then left in the solution from the completed 
batch experiment for 30 days on the bench. After 30 days, there was no detectable protein 
concentration in the supernatant, which confirms the lack of significant leeching of either 
enzyme from the resin due to the reaction buffer. After the resin was washed with 
NH4COOH solution at pH 8.5 to remove any remaining amine product, the 10 mL batch 
conversion was repeated to assess the long-term stability of the immobilized enzymes. In 
both cases, roughly 85% conversion was reached. Importantly, the measured time course 
 99 
for day 30 was virtually indistinguishable from the one measured on day 0, as can be seen 
in Figure 5-3. 
5.4.3 Binding Capacity 
The binding capacities of the Nuvia IMAC resin for both AmDH and FDH were 
determined using a continuous flow experiment through a packed column. A known 
concentration of enzyme was pumped through a packed column with a known quantity of 
empty Nuvia IMAC resin. The outlet from the reactor was collected into 96-well plates, 
and the change in enzyme concentration from the stock solution of each fraction was 
determined by measuring the absorbance at 280 nm. All the enzyme which is missing in 
the outlet solution was assumed to have bound to the resin. For both experiments, the 
enzyme stock solution ran out before the resin was completely saturated, so the binding 
curve was extrapolated to infinite time by assuming the binding isotherm is symmetric 
about the inflection point. Integration of the binding curves shown in Figure 5-4 yields the 























Figure 5-3 Batch conversions of 5-methyl-2-aminohexane by AmDH and FDH 
immobilized on Nuvia IMAC before and after 30 days of storage in NH4COOH buffer 
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of AmDH per mL of settled bed, or 440 mg per gram of dry resin. However, the binding 
capacity for FDH was just 42.1 mg per mL of settled bed, or 236 mg per gram of dry resin. 
Dry resin weight was calculated based on 64% random packing efficiency for spheres, the 
80% reported pore volume for Nuvia IMAC resin,171 and 1.11 g/mL density of 
polyacrylamide. The difference in binding capacity cannot be explained by differences in 
molecular weight, as the monomer masses of AmDH and FDH are 43.3 and 42.5 kDa, 
respectively. Instead, the inconsistency in binding capacity is likely due to differences in 
quaternary structure. FDH is known to form dimers in solution,172 while the AmDH likely 





Figure 5-4 Experimental binding curves of AmDH and FDH to Nuvia IMAC resin. 
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5.4.4 AmDH to FDH Binding Ratio 
While the binding capacities of the two enzymes on Nuvia IMAC resin are 
significantly different, the rate of binding was assumed to be the same. Mixtures containing 
saturating enzyme concentrations at different mass ratios of AmDH to FDH were incubated 
with 0.2 mL of resin for 24 hours. Then, the immobilized biocatalyst beads were employed 
in 50 mL scale for conversions of 20 mM 5M2H for 21 hours. As seen in Table 5-1, for 
the conditions tested, there was no optimum enzyme ratio. The condition which showed 
the maximum conversion after 21 hours was a 5:1 AmDH to FDH case. The benefits of 
increased AmDH concentration were likely offset by slower cofactor regeneration. An 
optimum AmDH to FDH ratio must exist somewhere above 5:1, but it was not investigated 
further in the reported work.  
Table 5-1  Comparison of enzyme binding ratios and the effect on batch conversion 
Enzyme Ratio total capacity 25% excess mg enzyme Conversion 
AmDH:FDH mg mg AmDH FDH % 
5:1 13.98 17.475 13.98 2.796 51.5 
2:1 12.18 15.225 9.744 4.872 48.8 
1:1 10.8 13.5 6.48 6.48 46.7 
1:2 9.7 12.125 3.88 7.76 44.8 
1:5 8.8 11 1.76 8.8 38.8 
5.4.5 Flow Characteristics of the Reactor System 
After the full flow reactor setup described in 5.3.8 was assembled, the physical 
parameters and flow characteristics were characterized first using empty resin absent of 
bound enzyme. After calibration of the electronic flow meters and generation of pump 
curves, the flow properties of the packed bed could be examined. When the Nuvia IMAC 
resin is properly packed, 2 mL of settled bed compresses to 1.58 mL in the column. The 
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flow properties of the system were examined using standard pulsed tracer experiments with 
NADH as the tracer. By following the absorbance at 340 nm in the outlet over time, the 
residence time distribution of the system at varying flow rates could be determined. A 
representative example of a collected RTD is shown in Figure 5-5. For an inlet flow rate 
of 0.574 mL/min, the mean residence time of the system, τsys was determined to be 9.78 
minutes. Importantly, this residence time includes not just the reactor, but all the tubing 
between the tracer injection point and the outlet of the fraction collector. The shape of the 
RTD shown in Figure 5-5 indicates a flow pattern in the system similar to a plug-flow 
reactor with a small dispersion effect, as evidenced by an estimated axial Péclet number of 
128. The RTD of the reactor alone in the absence of the rest of the system could not be 

















Figure 5-5 Residence time distribution at 0.574 mL/min 
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the actual packed bed. Also, the single clean peak in the RTD indicates proper packing of 
the reactor without significant channelling or dead volume. 
Prediction of the time to reach steady state without measuring conversion on-line 
was vital to operation of subsequent experiments. The total system volume Vsys was 
determined to be 5.80 mL by measuring τsys at various flow rates and fitting the resulting 
data to the simple relation τsys = Vsys/v where v is the volumetric flow rate in mL/min (see 
Figure 5-6). Once Vsys was determined, τsys could be predicted at any flow rate, and Figure 
5-5 shows that after two mean residence times have passed since tracer injection, the 
system has returned to a steady state. Thus, after any change in conditions, samples could 
be confidently collected after at least two times τsys and saved for later quantification. A 
similar set of experiments was conducted with twice the volume of resin, and Vsys was 
Figure 5-6 Dependence of mean residence time on flow rate in the packed bed reactor. 
The dashed line represents the function τsys = Vsys/v where Vsys was determined to be 5.80 
mL. 
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determined to be 7.07 mL. Thus, the actual reactor volume in the first set of RTD 
experiments, Vbed is the difference between the two measured system volumes, or 1.27 mL. 
Vbed was used to predict τbed, which is the residence time of the actual reactor for use in 
subsequent characterization. 
5.4.6 Continuous Amine Production: Initial Tests 
For an initial proof of concept, AmDH and FDH were coimmobilized directly from 
clarified lysate onto 2 mL (settled bed) of Nuvia IMAC resin. While the exact amount of 
protein immobilized onto the resin for this test is not known, it is estimated that roughly 25 
mg of FDH and 60 mg of AmDH were bound to the resin. This estimate comes from the 
measured yields of protein purified from a fraction of the same fermentation batch as was 
used for immobilization. The total amount of enzyme on the beads could be measured by 
elution of the bound protein from the resin with either a high concentration of imidazole or 
EDTA followed by quantification with the Bradford Assay. However, because the two 
enzymes were co-immobilized, it is not possible to determine the relative concentration of 
the two enzymes after elution with benchtop assays. Further development of the reactor 
platform was conducted with purified enzyme rather than lysate in order to give better 
control over relative enzyme concentrations on the beads. After packing the resin into a 
column, the effect of temperature on conversion was determined. As shown in Figure 5-7, 
increasing the temperature from 25 °C to 40 °C increased conversion by roughly 2.5-fold. 
When the natural log of the relative conversion is plotted versus the inverse of absolute 
temperature to produce an Arrhenius plot, a linear relationship is observed as expected. 
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The relative conversion has a linear relationship to the apparent rate constant, so its 
use in an Arrhenius plot is valid. Based on (17), the apparent activation energy, 𝐸𝑎
𝑎𝑝𝑝
, of 
the AmDH/FDH system is given by the slope of the Arrhenius plot multiplied by the gas 
constant, R, which has a value of 1.987x10-3 kcal mol-1 K-1. Based on the slope in Figure 
5-8 and (17), the apparent activation energy of the combined AmDH/FDH reactions was 












) + ln (A0) (17) 
Figure 5-7 Effect of temperature on reaction conversion of 5-methyl-2-hexanone in 
the packed bed reactor. Feed to the reactor consisted of 20 mM 5M2H, 1 mM NAD+, 
and 2 M NH4COOH/NH4OH adjusted to pH 8.5. 
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Because increasing temperatures often leads to decreases in enzyme stability, the 
apparent deactivation rates of the immobilized biocatalysts were determined at two 
temperatures. For both 30 °C and 40 °C, the change in conversion over five days appeared 
to follow a first order deactivation kinetic. Deactivation profiles over 120 hours at the two 
temperatures are shown in Figure 5-9. There was no significant decrease in stability at 40 
°C compared to 30 °C. The apparent half-life at 30 °C was 124 hours, while the apparent 
half-life at 40 °C was even longer, at 159 hours. 
Figure 5-8 Arrhenius plot of the observed relationship between conversion and 
temperature in the packed bed reactor 
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5.4.7 Improved Reaction Conditions 
Using the lessons learned from previous experiments, a final batch of immobilized 
enzyme was prepared and characterized. A 2 mL sample of Nuvia IMAC resin was 
saturated with AmDH and FDH in a 5:1 ratio by mass. With the reactor held at 40 °C, inlet 
flow rate was varied to determine the effect of residence time on conversion and 
productivity. The results of this experiment are displayed in Figure 5-10.  
Figure 5-10A shows the relationship between flow rate and reactor performance, 
while Figure 5-10B displays data from the same experiment, but in terms of residence time 
in the reactor rather than flow rate. The two different views of the data are useful for 
Figure 5-9 Apparent deactivation kinetics of immobilized FDH and AmDH under 
continuous flow conditions. Red points and curves represent reaction at 30 °C, while black 
points and curves and points represent reaction at 40 °C. Shaded regions represent the 95% 
confidence region on the first order deactivation fit. 
 109 
different ways of thinking about the experiment. The shape of the residence time versus 
conversion plot indicates an asymptotic conversion somewhat less than 100% at very long 
residence times. The flow rate plot, Figure 5-10A is more useful as a tool for actually 
operating the reactor, as flow rate is a readably controllable parameter. The maximum 
observed conversion, 48%, was at the largest residence time of 11.9 minutes and a flow 
rate of 106.8 μL/min, as expected. Conversion steadily decreased as flow rate was 
increased, with a minimum of 18.8% at 816 μL/min and a residence time of 1.55 minutes. 
Productivity was reasonably high at all flow rates, with a minimum value of 166 g/L/day 
at 106 μL/min and a maximum of 433 g/L/day at the second highest flow rate, 715 μL/min. 
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Figure 5-10 Impact of flow rate on conversion and productivity in the AmDH/FDH 
packed bed reactor. Feed to the reactor consisted of 20 mM 5M2H, 0.5 mM NAD+, and 
2 M NH4COOH/NH4OH adjusted to pH 8.5. Temperature was fixed at 40 °C. 
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5.5 Estimation of Limitations to Conversion 
Despite high volumetric productivities reported in 5.4.6, overall conversion was 
limited to just under 50% for the longest included residence time. Batch reactions with 
immobilized AmDH and FDH showed that conversions of 5-methyl-2-hexanone exceeding 
85% are possible. However, the shape of the residence time vs. conversion plot in Figure 
5-10B indicates it would likely require a residence time in excess of one hour to reach 90% 
conversion at the given reaction conditions, which would yield much decreased volumetric 
productivity. An exploration of the possible causes of limited conversion is important for 
future reactor development.  
5.5.1 Damköhler Numbers 
In 1936, Gerhard Damköhler published his seminal paper on the relationship 
between flow, diffusion, and kinetics in continuous reactors.173 In this discussion, we will 
focus on a set of parameters that have since become known as Damköhler Numbers (Da). 
A Damköhler number, broadly speaking, is the ratio of the chemical flux (the reaction rate 
per unit area) in a reactor to the mass flux (mass transfer rate per unit area). Put another 
way, it is the ratio of the characteristic time scale for mass transfer to the characteristic time 









The desired form of Da depends on the type of reaction in the reactor and the type 
of mass flux to be examined. The first form of Da described by Damköhler relates the 
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reaction rate to the rate of convective mass flux, and here will be called Da(I) and is defined 
in (19) for a reaction with rate -rA per unit volume, reactor with length L, substrate 
concentration CA and superficial fluid velocity USF. The length of the reactor divided by 















A value of Da(I) >> 1 indicates the time it takes for the substrate to flow through 
the reactor is much longer than the time it takes for the substrate to react. Thus, at high 
values of Da(I), complete conversion is expected. Likewise, low conversion is expected at 
low values of Da(I). For a first order reaction in an ideal plug flow reactor, the expression 





= 𝑘𝜏 (20) 
 𝑋 = 1 − 𝑒−𝐷𝑎(𝐼) (21) 
Section 5.5.2 will discuss modifications to (19) and (21) necessary to adequately 
describe the enzymatic reaction system used in this study. 
The second Damköhler number relates the reaction rate to the rate of diffusive mass 














In (22), l is some characteristic length, CA is the concentration of species A, -rA is 
the reaction rate per unit volume, and DA is the diffusion coefficient of species A. The value 
of Da(II) can reveal information about the timescales required for reaction and for diffusion. 
If Da(II) is very large, then the intrinsic rate of reaction is much larger than the rate of 
diffusion. As such, the catalyst will react with the substrate much faster than the substrate 
can diffuse from the bulk to the catalyst. A large value of Da(II) results in a lower than 
expected observed reaction rate and an under-utilized catalyst. The relationship between 
the observed reaction rate and the maximum reaction rate that would be observed without 
diffusion limitations is known as the effectiveness factor, η. In a packed bed reactor with 
porous beads, the specific form of Da(II) depends on whether one is interested in diffusion 
limitations inside the beads or limitations between the bulk fluid and the bead surface. 
Internal mass transfer limitations will be discussed in 5.5.3 while external mass transfer 
limitations will be discussed in 5.5.4. 
5.5.2 Enzyme Kinetics 
5.5.2.1 Assumptions 
The most basic analyses of biocatalytic processes assume that the expression for 










While reaction kinetics of the reactor system presented in this study are much more 
complicated than (23), as was discussed in detail in CHAPTER 3, the simplifying 
assumptions needed for (23) to be potentially useful are reasonable and are listed below. 
1) Full conversion of NAD+ by FDH is fast enough that the concentration of NADH 
is constant over the length of the reactor and is close to the inlet concentration of 
NAD+, 0.5 mM.  
2) The concentration of NH3 in the reaction is constant over time. 
3) There is no significant product inhibition. 
4) The expression Vmax = kcat[E] is true for the relevant enzyme concentration [E] in 
the reactor of 2.5 mM 
Based on reported literature values for FDH, the kcat value is estimated to be 8.06 s
-1, 
which is significantly higher than estimated value for AmDH of 1.75 s-1. Thus, Assumption 
1 is likely valid to a reasonable approximation. Since the concentration of NH4COOH in 
the feed is 2.0 M and the maximum possible change in ammonia concentration is 20 mM, 
Assumption 2 is also reasonable. 
In the literature on continuous reaction engineering with immobilized enzymes, it is 
common to further assume (Assumption 5) the rate of the reaction in the reactor can be 
accurately described as a first order reaction with a rate constant equal to either Vmax/KM 
or Vmax/CA,0 where CA,0 is the inlet concentration of the substrate.
175-185 This results in a 
very simple expression for Da(I) shown in (24) and equally simple expressions for Da(II) 







For the experimental results shown in Figure 5-10, the enzyme concentration [E] was 
2.5 mM, and initial rate experiments yielded kcat and KM values of 1.75 s
-1 and 4 mM, 
respectively. Applying (24) with these values at a residence time of 3.9 minutes yields an 
expected value for Da(I) of 254.6, and conversion based on (21) of 100%. Experimental 
results, instead, showed a conversion of 33.6% when the residence time was set at 3.9 
minutes. In fact, conversion would be expected to be 99.5% with a residence time of 5.0 
seconds if (24) were valid for the reactor system studied here.  
5.5.2.2 High Enzyme Concentration 
One of the fundamental assumptions of the Michaelis Menten equation is that the 
concentration of enzyme in solution is much less than the concentrations of and KM values 
of the substrates involved in the reaction. In the experiments which produced Figure 5-10, 
the enzyme concentration was 2.5 mM, while the concentration on NADH in the reactor 
was at most 0.5 mM. Additionally, the KM,NADH for AmDH is approximately 0.0125 mM. 
The reaction conditions are not consistent with the low enzyme concentration assumption 
when NADH is concerned. A more general rate law, (25), can be used to describe single-
substrate kinetics without inhibition at any ratio of enzyme to substrate.186-187 The 
magnitude of the relative error between (23) and (25) at various concentrations of enzyme 





𝐾𝑀 + [𝑆] + [𝐸] + √(𝐾𝑀 + [𝑆] + [𝐸])2 − 4[𝑆][𝐸]
 (25) 
 Based on assumption 1 from 5.5.2.1, the concentration of NADH is expected to be 
relatively constant at around 0.5 mM, which is much higher than the KM value of 0.0125 
mM and much lower than the 2.5 mM AmDH concentration. As a result, the substrate is 
Figure 5-11 Relative percent error in the Michaelis Menten equation at various 
enzyme and substrate concentrations. The black bars represent the accessible 
concentration ranges for 5-methyl-2-hexanone and NADH in the experiments which 
produced Figure 5-10. The numbers below the “Ketone” bar refer to the conversion value 
at the location along the bar. Numbers in the white boxes inside the plot refer to the value 
of the relative error along that line. 
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completely saturated with enzyme, and adding additional enzyme will not increase the 
reaction rate. This the opposite situation of the classic Michaelis Menten case, where 
enzyme is saturated when [S] >> KM. Under the chosen reaction conditions, Assumption 4 
from 5.5.2.1 is clearly invalid. The apparent maximum velocity Vmax,app is given by (26), 
where Vmax is multiplied by the ratio of (25) and (23) and then simplified for the case that 









[𝑆] + [𝐸] + √([𝑆] − [𝐸])2
𝑘𝑐𝑎𝑡[𝐸] (26) 
Equation (26) was evaluated for [NADH] = 0.5 mM and [E] = 2.5 mM to give the final 
expression for Vmax,app shown in (27). 
 𝑉𝑚𝑎𝑥,𝑎𝑝𝑝 = 0.203𝑘𝑐𝑎𝑡[𝐸] (27) 
5.5.2.3 Product Inhibition 
The extent of product inhibition of AmDH by 5-methyl-2-aminohexane was 
examined via initial rate experiments with soluble enzyme. The reaction rate was 
determined at various simulated levels of conversion by mixing various combinations of 
concentrations amine and ketone, each of which added to a total of 20 mM. Figure 5-12 
shows that, like was seen for a different amine dehydrogenase in CHAPTER 3, AmDH is 








) + 𝐶𝐴,0(1 − 𝑋)
 
(28) 
In this rate law, CA,0 is the starting ketone concentration, X is conversion, KM is the 
Michaelis constant for the ketone, and KI is the inhibition constant for the amine product. 
The fit values for KM and KI were 3.54 mM and 1.54 mM, respectively. Given these results, 
both Assumption 3 and Assumption 5 from 5.5.2.1 are invalid for the current AmDH 
reaction. 
Figure 5-12 Relationship between conversion and reaction rate for AmDH amination 
of 5-methyl-2-hexanone. Circular data points represent the results of individual initial rate 
assays with simulated levels of conversion of 20 mM 5-methly-2-hexanone between 0.0 
and 0.9. The solid black curve represents a nonlinear fit of the initial rate data to (28), the 
rate law for competitive inhibition, the hashed red curve represents the expected activity 
vs. conversion curve for Michaelis Menten kinetics, and the hashed black curve is a fit of 
the initial rate data to a standard second order reaction kinetic. 
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5.5.2.4 The Improved Rate Law and Da(I) 
Given the results from 5.5.2.2 and 5.5.2.3, an improved form of the rate law as a function 








) + 𝐶𝐴,0(1 − 𝑋)
=




) + 𝐶𝐴,0(1 − 𝑋)
 
(29) 
As shown in Figure 5-12, the rate of reaction changes constantly with conversion, 
and is neither in the first-order nor the zero-order regime. Thus, there is not a single value 
of Da(I) which is valid over the entire length of the reactor. To arrive at a single average 
value for Da(I), one can take the integral of Da(I) with respect to conversion from 0% to 
100% at a given residence time τ, as shown in (30).  
 










For a residence time of 3.9 minutes, (30) predicts a Da(I) value of 4.6. Because the 
AmDH kinetics roughly approximate a second order power law kinetic (see Figure 5-12),  









= 0.82 (31) 
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While 82% conversion is still much higher than the observed conversion of 33.6%, 
it is not unreasonably high, and is much more accurate than the conversion value estimated 
in 5.5.2.1. 
5.5.3 Internal Mass Transfer 
If the rate of internal diffusion through the pores of the beads in a packed bed is 
slower than the rate of intrinsic kinetics, then the overall conversion in the reactor will be 
lower than would be observed if all the enzyme were at the bead surface and thus internal 
diffusion were unimportant. The Thiele modulus, ϕm, is often used to describe the 
relationship between a reaction rate at the catalyst surface to a rate of diffusion within the 
catalyst particle.160 The American engineer Ernst Thiele and German Damköhler both 
worked in this area in parallel but separate fashions in the late 1930s.188 Although Thiele 
likely was not aware of Damköhler’s work at the time, his modulus can be defined in terms 
of a form of a Damköhler number for internal pore diffusion, Da(II),i where the characteristic 











  (32) 
In (32), dp is the bead diameter (49x10
-6 m) and -rAs is the reaction rate per unit 
volume at surface concentration CAs of 5-methyl-2-hexanone as defined in 5.5.2.4. The 
effective diffusivity of ketone inside the pores, DA,eff, is the bulk diffusivity multiplied by 
a factor of εbead/τbead which is defined as the porosity (εbead = 0.8)
171 divided by the tortuosity 
(estimated to be 3.0) of the Nuvia IMAC beads. The bulk diffusivity of 5M2H at 40 °C 
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was assumed to be roughly equal to the infinite dilution diffusivity at that temperature, 1.06 
x 10-9 m2/s.189 This results in an effective diffusivity inside the pores of 2.83 x 10-10 m2/s. 
While the assumed value of the diffusivity is likely inaccurate due to the high ionic strength 
present in the reaction buffer, recalculation of the transport parameters in the following 
sections with a 100-fold lower estimation of the diffusivity did not change the conclusions. 
At very low values of the ϕm, pore diffusion is much faster than the reaction, so diffusion 
limitations can be neglected. At the reactor inlet, where the reaction rate is the highest and 
the effects of mass transfer limitations would be greatest, ϕm was estimated to be 0.091. 
The very low value of ϕm yields an internal effectiveness factor, ηI, greater than 0.99 which 
indicates no impact of internal mass transfer limitations in the reactor.160 
The volumetric productivities (in g/L/day) from the continuous reactor measured 
in 5.4.6, after unit conversion to mol/m3/s, are equivalent to the average observed rate of 
reaction over the entire reactor, -rA(obs), and were used to further verify the absence of 






≪ 1 (33) 
CA,f in (33) is the outlet concentration of ketone after the system had reached steady state. 
For all inlet flow rates recorded CW-P was less than 0.01, which satisfies the criterion. The 
very small 49 μm particle diameter of the Nuvia IMAC resin is very effective at avoiding 
internal diffusion resistance for small molecules. 
5.5.4 External Mass Transfer 
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Even though internal mass transfer limitations can be neglected, the impact of 
external mass transfer from the bulk fluid to the resin beads needed to be considered. 
Predictions of the impact of external mass transfer were made by computing the external 
mass transfer Damköhler number, Da(II),ex, which is the ratio of the reaction rate to the rate 
of diffusive mass transfer from the bulk fluid to the bead surface. The value for Da(II),ex(X) 
at any point along the reactor is a function of the conversion, because the reaction rate and 
diffusion rate are both strongly dependent on the concentration of substrate. To give an 
average value of Da(II),ex across all concentration ranges, the instantaneous Damköhler 
number is integrated from X=0 to X=1. 
 











In (34), X is conversion, CA,0 is the inlet ketone concentration (20 mol/m
3), and ϕbed is the 
packed bed void fraction which was assumed to be 0.3. The values of kL, the external mass 
transfer coefficient, and a, the volume averaged interfacial area, were estimated using (35) 











The Sherwood number, Sh was estimated based on (37), a correlation incorporates the 
Reynolds (Re) and Schmidt (Sc) numbers and is valid under conditions of creeping flow.191 
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For all flow rates in the reported work, Re is less than 1x10-4, which is consistent with 
creeping flow. Sc, which is independent of flow rate, is estimated to be 8.04x105. 
 𝑆ℎ = 2 + 0.991(𝑅𝑒 𝑆𝑐)1/3 (37) 





 ,   𝑅𝑒 =
𝑈𝑆𝐹 𝑑𝑝
𝜈




The kinematic viscosity 𝜈 for 2M NH4COOH was measured using a capillary viscometer 
at 22 °C and was found to be 30% higher than that of pure water at the same temperature 
and it was assumed the relationship holds true at 40 °C.192 In the equation above for 
superficial fluid velocity, USF, the reactor diameter dr and volumetric flow rate vf were 
measured directly. Typical values of Sh for the flow rates relevant to this study are 
predicted to be between 3.0 and 4.2. For all flow rates and conversion values relevant to 
the reported reaction system, the predicted value of Da(II),ex is less than 0.003. From the 
Damköhler number, the external effectiveness factor, ηE was determined using (38) and 
was greater than 0.99 for all relevant flow rates and conversions.176 While (38) is only 
strictly valid for a second order kinetics, Figure 5-12 shows that a second order rate law is 
a reasonable approximation for the real kinetics in the system.  
 
𝜂𝐸 =
√1 + 4𝐷𝑎(𝐼𝐼),𝑒𝑥 − 1
2𝐷𝑎(𝐼𝐼),𝑒𝑥
     (38) 
As was the case with internal mass transfer, no limitations on conversion are 
expected due to external mass transfer. This is due to the very small diameter of the Nuvia 
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IMAC beads. A 10-fold increase in the bead diameter to 490 µm would yield a 100-fold 
increase in Da(II),ex, and ηE values as low as 0.8. Further confirmation of the lack of external 
mass transfer limitations was accomplished with a version of the Mears criterion which has 
been modified for enzyme kinetics.193-194 External mass transfer limitations can be ignored 



















Over the range of flow rates relevant to this study, values of the left-hand side of (39) 
ranged from 1.59x10-4 to 2.34x10-4 while the values of the right-hand side of (39) ranged 
from 0.06 to 0.08. Thus, for all flow rates examined in the reported work, the modified 
Mears criterion is satisfied and external mass transfer limitations can be neglected. 
5.6 Discussion 
We have demonstrated the first continuous flow reaction system to enantiomerically 
pure (R)-amines with co-immobilized AmDH and FDH which is stable for more than 24 
hours of operation. Additionally, the system remained operational, with reductions in 
activity, for more than a week and the system is as stable at 40 °C as it is at 30 °C. 
Conversion of 20 mM 5-methyl-2-hexanone increased with decreasing flow rate and 
ranged between 19% and 48%. However, decreased conversion resulted in increased 
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volumetric productivity, which ranged from 107 g/L/day at 48% conversion up to a 
maximum of 443 g/L/day at 24% conversion. 
The relationship between conversion and productivity is a key design constraint to 
consider when engineering a continuous chemical process.  The choice of whether to favor 
conversion at the expense of productivity in the reactor or vice versa should be based on 
the requirements and costs of the unit operations surrounding it and cannot be made based 
solely on the results in the present study. Without knowledge of the economics of the rest 
of the process, the optimal operating point for the enzyme reactor cannot be determined. If 
enzyme and resin are expensive, but separation is cheap, then operating at a lower 
conversion with a post-separation recycle stream might be preferable. However, if 
separating ketone from amine is expensive, then higher conversion per-pass would be 
desired at the expense of higher costs for enzyme or resin. 
  Binding of the enzyme to the Nuvia IMAC resin was shown to be tight and stable 
under reaction conditions. The very small diameter of the resin beads of 49 µm resulted in 
excellent mass transfer properties and no limitations due to internal or external diffusion 
rates. The specific binding capacities of the resin for AmDH and FDH were determined to 
be 78.3 mg/mL and 42.1 mg/mL respectively. After batch experiments at varying enzyme 
ratios, a 5:1 ratio of AmDH to FDH was chosen to maximize conversion. However, when 
saturated resin was packed into the reactor, the AmDH concentration was much higher than 
the cofactor concentration, which caused 80% of the enzyme to go un-utilized. Depending 
on the costs of the components involved, the underutilization of enzyme could be alleviated 
by increasing the cofactor concentration, or by utilizing the same amount of enzyme but 
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spread over more resin. Inhibition by the chiral amine product also represented a significant 
impact to conversion at reasonable productivity levels.  
While more can be done to optimize the system, the reported work represents an 





CHAPTER 6. FUTURE PERSPECTIVES 
6.1 Protein Engineering 
6.1.1 Motivation for Protein Engineering Work 
While it was not discussed in CHAPTER 2 or the published manuscript on protein 
engineering toward improving the L-AmDH,79 the primary motivation for the protein 
engineering project was to gain activity toward 5-diethylamino-2-pentanone. The resulting 
(R)-2-amino-5-diethylaminopentane is a key intermediate toward the production an 
enantiopure form of the antimalarial drug chloroquine, as shown in the reaction scheme in 
Figure 6-1. 
 Chloroquine is currently sold as a racemic mixture as a malaria prophylactic 
treatment, as well as a treatment for certain autoimmune diseases like lupus and rheumatoid 
arthritis. In February of 2020, interest in chloroquine and the structurally related 
hydroxychloroquine exploded for the potential treatment for and prophylaxis against 
COVID-19, the pandemic infections disease caused by severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2).195-197 However, the work in this thesis was conducted and 
completed well before the start of the COVID-19 crisis. Chloroquine has been regarded as 
safe since the late 1940s, but there are still some serious side effects associated with the 
Figure 6-1 Obtaining (R)-chloroquine with the help of L-AmDH 
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drug including nausea, deafness, blindness, heart failure, anemia, etc. There has been some 
evidence that these side effects may be caused more by the (S)-enantiomer than the (R)-
enantiomer of chloroquine.198 As a result, it was desirable to develop a scalable synthesis 
for (R)-chloroquine. 
The base case L-AmDH published by Abrahamson et. al in 20122 is only active on 
ketones the size of 2-hexanone or smaller, and also is not active on any methyl ketones 
with terminal tertiary amine groups. We employed a strategy of substrate walking38 to 
attempt to achieve activity toward the target 5-diethylamino-2-pentanone (5DAP) by 
introducing mutations to the base case enzyme which would instill activity toward 
substrates which could be thought of as intermediate steps between 2-hexanone and 5DAP. 
The series of intermediate substrates is shown in Figure 6-2. 
The first step was to increase the size of the binding pocket, which was accomplished 
with L39A and L39G mutations. Then activity toward longer branched ketones was 
enabled by A112G and T133G.79 Finally, activity toward a number of tertiary amino 
ketones was tested with multiple enzyme variants including TV/L39A, TV/L39G, and 
Figure 6-2 Steps in the substrate walk toward 5DAP 
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TV/A112G/T133G. These tertiary amino ketones included 3-dimethylamino-2-propanone, 
3-diethylamino-2-propanone, 4-dimethylamino-2-butanone, 4-diethylamino-2-butanone, 
5-dimethylamino-2-pentanone, and finally the target 5-diethylamino-2-pentanone. No 
activity was found for any of these ketones except for low but measurable activity for 4-
diethylamino-2-butanone (23 mU/mg for TV/L39A, 21 mU/mg for TV/L39G, and 12 
mU/mg for TV/A112G/T133G). The L39A/V293T mutation was attempted to provide a 
potential hydrogen bonding partner for the amine group on 5DAP, the resulting enzyme 
was not dead, but did not show improvement in activity for any substrate over the L39A 
variant on its own. 
6.1.2 Directed Evolution for AmDH Engineering 
6.1.2.1 The Need for Libraries 
All the published mutations to the L-AmDH presented in this thesis were single 
point mutations, with one variant produced at a time. While there were some successful 
mutations, there were just as many, if not more unsuccessful ones. The amount of labor 
required to produce a single point mutation, especially one not based on previously 
reported in the literature for related enzymes, may not be worth the small probability of 
success. As such, a broader approach to mutations is necessary, where multiple mutants 
are created at once, and the resulting libraries are screened for desirable activity. Library 
generation and screening is ubiquitous for protein engineering projects, and more work in 
this area must be performed for further AmDH development. 
6.1.2.2 Limitations to Library Size 
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The largest libraries found in protein engineering projects are generated by error-
prone PCR, where DNA polymerase with a high error rate is used to generate one or more 
random mutations per copy of the gene. In this manner, libraries with thousands or millions 
of different individual colonies can be generated. However, the speed of the functional 
assay determines how large a library for a study can be. For antibody engineering or other 
systems with surface display, a high-throughput fluorescent assay can be developed which 
can allow for screening of millions of colonies with a FACS system.199 There have also 
been some clever examples which used a fluorescent assay in a water-oil emulsion to sort 
and screen enzyme libraries with FACS.200 
The current assay used for screening AmDH libraries is much slower than any of the 
cell sorting based assays. For library screening, the activity of L-AmDH is measured in the 
oxidative deamination direction by following the increase in absorbance at 340 nm due to 
the conversion of NAD+ to NADH. The reductive amination direction is not suitable, 
because endogenous NADH oxidases present in E. coli cells result in too many false-
positive results. Because the activity assay is based on absorbance, it must be measured in 
free solution, after cell lysis and clarification. Colonies from agar plates containing the 
library to be screened are picked into 96 well plates filled with autoinduction media. After 
cell growth and expression overnight in an incubator, the cells are lysed using a chemical 
lysing agent like B-Per and centrifuged to remove cell debris. Afterward, the resulting 
clarified lysates are split into two separate 96-well plates and the activity in one plate is 
compared to the background absorbance increase in the other. This assay is quite tedious 
and limits feasible library sizes to the low thousands, which makes error prone PCR 
strategies less appealing. 
 131 
6.1.2.3 Site-Directed Libraries 
A compromise between random mutagenesis and single point mutations is the 
generation of libraries which contain multiple variants with mutations at the same site or 
handful of sites. Screening of larger libraries gives a greater chance of obtaining beneficial 
mutations. If a site-saturation library with an NNK codon at a potentially interesting site is 
generated, 96 colonies are required to be screened in order to achieve a theoretical 95% 
sequence coverage.201 A single screening plate per site can be readily accomplished. If 
several variants at two individual sites are promising, a site-saturation library which 
contains both sites can be constructed. As the number of sites increases, however, so too 
does the number of colonies required to be screened for 95% coverage. 3066 colonies are 
needed for a 2-site library, while 98,163 are needed for a 3-site library.202 In 2019, a plan 
was developed to try to achieve make the final step in the substrate walk toward 5-
diethylamino-2-pentanone by creating several site saturation libraries at a handful of 
residues in the active site of the L-AmDH/TV/L39A. The sites were chosen based on 
homology modelling of the variant with a published crystal structure of the Geobacillus 
stearothermophilus LeuDH and rudimentary docking simulations with the target substrate 
using Audodock Vina. Residues were chosen based on their distance from the potential site 
of the tertiary amine group on the substrate. Residues considered for site saturation libraries 
are shown in FIGURE 6-3. Unfortunately, setbacks in generation of the libraries prevented 
significant progress. The chosen mutation sites may be a potential starting point for future 
work on L-AmDH, even if the future target substrate is not 5DAP. 
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Figure 6-3 Potential sites for site-saturation libraries in L-AmDH/TV/L39A 
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6.1.2.4 The Future of Protein Engineering for AmDHs 
While single-site saturation libraries, like the ones described in the previous section 
may produce successful variants, the selection of sites is still based largely on visual 
inspection of crystal structures. Such strategies employed in this reported thesis work 
cannot compete in the modern protein engineering landscape. Computational protein 
engineering and large-scale screening efforts such as those conducted by companies such 
as Codexis show a clear picture of where protein engineering for industrial biocatalysis is 
going. Any future effort toward engineering new or better activity in AmDHs by the 
Bommarius group should seek to leverage modern computational protein design tools. It is 
outside the scope of this thesis to provide a detailed discussion of these tools. However, a 
good starting point would be the recent work out of the Baker,203 Siegel,204 and 
Whitehead205 groups.   
6.2 Understanding the Kinetics of Amine Dehydrogenases 
6.2.1 Motivation: Binding of Ammonia 
Initially, the goal of studying AmDH reaction kinetics in more detail than had been 
done previously was to solve the problem of ammonia binding. The AmDH reaction 
requires a very high concentration of an ammonium salt for significant turnover to be 
achieved. The standard reaction conditions in the continuous reactor calls for 2M 
ammonium formate at pH 8.5. This high ammonium salt concentration can potentially lead 
to undesirable side reactions, protein instability, and corrosion of reactor components. For 
Samantha Au, the PhD student who worked on this project from 2012 to 2016, a primary 
aim of her thesis project was to improve ammonia binding to AmDH through protein 
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engineering.123 Her efforts toward this goal were ultimately not successful, and when the 
present thesis work was proposed, a similar goal was laid out to improve ammonia binding.  
To start attacking the problem, we decided to take a step back and try to understand 
what (if any) fundamental differences existed between AmDH kinetics and the kinetics of 
their parent amino acid dehydrogenases. It was thought that the results of the mechanism 
study may guide future protein engineering efforts to improve ammonia binding. In the 
literature, the reported KM values for ammonia for leucine dehydrogenases were all lower 
than 300 mM, while the KM values for ammonia in L-AmDH was initially found to be 
between 1 and 2 M. We wanted to understand if the large difference in ammonia KM 
between the engineered and parent enzymes was the result of some fundamental change in 
the reaction kinetics. The basic assumption made by our group had been that the AmDH 
and AADH had the same type of kinetics, but with different rates. One of the most 
surprising outcomes of the thesis project was disproving that assumption. 
6.2.2 Ammonia Does Not Bind to the Enzyme 
The results of the kinetic studies outlined in Table 3-1 show that the apparent KM 
values for ammonium chloride are much higher than were previously reported for L-
AmDH or LeuDHs.55 For L-AmDH and LeuDH, the apparent KM values were 7.8 M and 
3.9 M, respectively. It was impossible to put enough ammonium chloride into solution to 
saturate either of the enzymes, and the KM value of NH4Cl estimated by for L-AmDH was 
higher than the solubility limit of NH4Cl. This led us to believe that there is no true binding 
of ammonia to the enzyme, but rather ammonia interacts directly with the bound ketone to 
form an imine, which is then reduced to the product amine. As we proposed in the paper,55 
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ammonia cannot “bind” to the enzyme without ketone already bound. Because there was 
no direct binding site of ammonia, further attempts to enhance ammonia binding through 
protein engineering were abandoned. It is possible that enzyme engineering work toward 
stabilizing the ketone-imine transition state may result in enhanced activity of AmDHs at 
lower ammonium salt loading, but that idea was not explored in the reported work. 
6.2.3 Further Exploration of AmDH Kinetics 
Beyond comparing an engineered enzyme to its parent, the techniques used in 
CHAPTER 3 could be employed to answer other lingering questions about the nature of 
AmDH kinetics. A few of those potential questions will be introduced in this section. 
6.2.3.1 How Does the Kinetic Mechanism Depend on pH? 
All assays in CHAPTER 3 were performed at pH 8.5 for the sake of experimental 
consistency. While this is not the pH value at which the AmDH shows maximum activity, 
it was the pH value chosen for reactor engineering studies due to stability concerns for 
AmDH and FDH. It may be interesting to compare the L-AmDH rate law at pH 9.9 to the 
rate law at pH 8.5. Both values are 0.7 pH units away from the pKa value of the ammonium 
ion, which is 9.26 and it is possible that the rate law for AmDH looks very different when 
operating above the ammonia pKa value. Care must be taken in sample preparation and 
storage, however, because the evaporation of ammonia from a buffer at pH 9.9 will be 
much more rapid than from a buffer at pH 8.5. 
6.2.3.2 How do Other Enzymes Compare to LeuDH and L-AmDH? 
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In addition to L-AmDH, the Bommarius group has access to a wide variety of other 
enzymes in the AmDH family. It would be interesting to see if the relationship between F-
AmDH and its parent PheDH is the same as the relationship reported between L-AmDH 
and its parent LeuDH. Bacillus badius PheDH and Geobacillus stearothermophilus LeuDH 
have strong structural and sequence similarity, but their substrate profile and activity levels 
are quite different from one another. Obtaining the rate law for F-AmDH will be much 
more difficult than L-AmDH, however. This is because the substrate, phenylpyruvate, 
absorbs light at 340 nm, which interferes with the rate assay, and it degrades in ammonia 
buffers over time. Great care must be taken to mitigate these challenges. 
Additionally, comparisons could be drawn between the F-AmDH, cFL1-AmDH, and 
L-AmDH to determine what differences in the enzyme kinetics resulted from the domain 
shuffling required to create a chimeric enzyme. At the time of writing, work toward 
determining the kinetic mechanism for cFL1-AmDH for the reductive amination of 2-
hexanone is ongoing, but with no concrete results to report. 
6.2.3.3 What Kinetic Differences Exist for the Reactions of Different Substrates by the 
Same Enzyme? 
A single AmDH may have activity towards dozens of different substrates, all with 
differing specific activities. The rate law fitting and kinetic solvent viscosity effect assays 
used to compare L-AmDH and LeuDH could be used to compare activity toward aromatic 
and aliphatic ketones by cFL1-AmDH. Because the structure of 2-hexanone and 
acetophenone, for example, are so different, the binding modes and rates of binding may 
be completely different between the enzymes. Additionally, the relative importance of 
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different steps in the kinetic mechanism could be explored by comparing the kinetics of 
two substrates which are structurally similar, but have very different specific activities, 
such as 2-butanone and 2-pentanone for the L-AmDH.120  
6.3 Reaction Engineering for the Production of Chiral Amines 
The efforts in early 2020 to fully characterize and optimize the reaction platform 
described in CHAPTER 5 were severely hampered by the COVID-19 crisis. Several 
questions about the system remain which were unable to be explored by further 
experimentation in March, April, or May of that year. The following sections are mostly 
focused on the remaining questions, whether they need to be answered, and some ideas for 
experiments that would be useful to get started on answering them. If prediction of 
conversion and estimation of mass transfer limitations are desired, then more work needs 
to be done to test the validity of many of the assumptions made in the calculations found 
in CHAPTER 5. 
6.3.1 Obtaining Improved Physical Parameters 
6.3.1.1 Intrinsic Enzyme Kinetics 
The steady state, free enzyme kinetics for cFL1-AmDH amination of 5-methyl-2-
hexanone (5M2H) were never measured at 40 °C, but rather the rate constant at that 
temperature was estimated based on the apparent activation energy, 12.4 kcal/mol,  
calculated in 5.4.6 and the specific activity measured at room temperature, roughly 21 °C. 
The steady state kinetics for FDH were estimated purely based on literature sources.172 
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Care should be taken to determine the true intrinsic kinetic constants for both enzymes 
under the desired process conditions. 
Additionally, the full inhibition profile should be measured for cFL1-AmDH, 
similar to the experiments conducted to measure the inhibition patterns for L-AmDH and 
LeuDH in Franklin, 2019.55 The results shown in Figure 5-12 were from a single 
experiment which was not repeated before the shutdown. More data at the process 
temperature will provide a much more reliable value for the inhibition constant for the 
amine product. The inhibition constant for NAD+ is also necessary to fully describe the 
kinetics. Cross inhibition between enzymes should also be examined to determine if the 
ketone substrate or amine product of the AmDH have any inhibitory effect on the formate 
dehydrogenase.  
It has been shown by the Bommarius group that the AmDH reaction rate is of the 
AmDH is dependent on the counterion chosen for the ammonium salt. AmDH shows a 
lower activity in ammonium formate compared to the same concentration of ammonium 
chloride. This effect is likely due in part to the increase in viscosity of ammonium formate 
solutions compared to ammonium chloride. However, high concentrations of chloride are 
often undesirable due to the corrosive effects of chloride ions on metal vessels. Because 
some amount of formate is needed for the FDH reaction to proceed, it may be useful to do 
a full exploration of potential mixtures of ammonium counterions and their effects on 
AmDH and FDH reaction rates.   
Finally, it was assumed that the immobilization of the two dehydrogenases to the 
Nuvia IMAC resin had no impact on the intrinsic kinetics of the enzymes. This assumption 
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should be rigorously examined. While it is likely to be true, as high levels of activity 
retention were observed for similarly immobilized enzymes other processes,170 each 
enzyme is different and must be individually validated. For each individual enzyme, a 
known small amount of enzyme should be immobilised onto the resin, and that resin should 
be added to a known volume of substrate solution at the process temperature 
(5M2H/NH4COOH/NADH for AmDH and NH4COOH/NAD
+ for FDH) and the reaction 
rate followed by UV/VIS absorbance over time. After conducting these assays at multiple 
concentrations of substrates, the resulting specific activities should be compared to the free 
solution kinetics obtained under the same conditions to determine any impact of 
immobilization on intrinsic kinetics. 
6.3.1.2 Fluid Properties 
Reasonable estimates for the overall mass transfer coefficient and effective pore 
diffusivity are required for internal and external Damköhler number calculations, as well 
as the calculations for the Mears and Weisz-Prater criterions. Like the reaction rates in the 
previous section, the viscosity and density values needed to determine the Sherwood 
number and thus the mass transfer coefficient were measured at 25 °C and extrapolated to 
40 °C. Measurements of the viscosity and density values of the actual process inlet solution 
at the process temperature are easy to perform and would be preferable to estimated values.  
The diffusion coefficient of 5M2H was assumed to be close to the infinite dilution 
diffusion coefficient of 5M2H in water at 40 °C.189 Better methods of measuring or 
estimating the free-solution diffusion behavior of 5M2H, as well as the other important 
small molecules in the system should be explored in more detail. Additionally, the effective 
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diffusivity of 5M2H was estimated based on the measured porosity of Nuvia IMAC beads, 
and an estimated value for tortuosity. The actual effective diffusion coefficient of each of 
the substrates and products inside the beads can measured at the process conditions using 
the method outlined by Grunwald in 1989206 and utilized in support of a cephalexin 
synthesis study in 2012.207 
6.3.2 Other Assumptions That Need to be Tested 
6.3.2.1 Interplay Between AmDH and FDH 
One of the largest simplifying assumptions which enabled the calculations in 
Section 5.5 was that the conversion of the NAD+ in the feed to NADH by formate 
dehydrogenase is nearly complete and very fast. Additionally, the concentration of NADH 
was assumed to be constant over the length of the reactor. This assumption allowed the real 
system, which contains two co-immobilized enzymes operating simultaneously, to be 
modelled as a single enzyme system with single-substrate kinetics. While the assumption 
was very useful, it is necessary to determine to what extent it is valid. If the conversion of 
NAD+ is not complete or fast, the resulting nonideality may have contributed to the 
prediction of much higher conversion values than were measured. 
As a first step toward testing the constant [NADH] assumption, the intrinsic kcat 
values for FDH and AmDH should be determined at the process conditions as discussed in 
6.3.1.1. A comparison of the more accurate rate constants will give a clearer picture of 
what is going on in the reactor. Additional experiments could be conducted by first 
generating a large batch of co-immobilized biocatalyst. Portions of the large batch of 
immobilized enzyme could be packed into the reactor at different bed heights and installed 
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into the continuous reactor setup described in 5.3.8. The conversion at the outlet can be 
measured by HPLC, and importantly the outlet NADH concentration can be measured by 
UV/VIS spectroscopy. If the constant [NADH] assumption is valid, then [NADH] in the 
outlet will be independent of bed height. Additionally, if the constant [NADH] assumption 
is valid, then the bed residence time vs. conversion plots at varied bed heights should 
overlay perfectly. 
6.3.2.2 Stability of Inlet and Outlet Solutions 
Another major assumption required to make the experimental methods for 
characterizing the system tractable was that the substrates in the inlet solution and amine 
in the outlet solution of the reactor are stable on the bench for at least a day. The inlet is 
stored in a glass bottle which is not airtight, but has a small opening in the cap. The outlet 
of the reactor is collected into open test tubes using an automated fraction collector. 
Additionally, it was assumed that the amine product in the outlet is stable for at least 5 days 
at 4 °C. This assumption was made so that the measurement of many outlet samples could 
be made at once, and so that only one bottle of the inlet solution needed to be made per 
day. The experiments to test the assumed stability of the inlet and outlet solutions are 
straightforward, but necessary to obtain a robust process. 
6.3.3 Is Predictive Modelling of the Reactor System Useful? 
The work described in 6.3.1 and 6.3.2 will certainly result in a more reliable model 
for predicting reactor performance than the one outlined in CHAPTER 5. However, it is 
prudent to ask if such a predictive model would be useful, or whether the complications 
introduced by the nonidealities in the system would render the model too difficult to fit, or 
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too specific to the tested conditions to be used for process optimization. For a process meant 
to run for multiple days, phenomena such as the relative deactivation rates of both enzymes 
and potential fouling of the enzyme support would also need to be included in a predictive 
model. Can such a model be developed with the tools, theory, time, and expertise available 
to the researchers? A serious evaluation of the limitations of any model produced should 
be made before significant resources are put into a task which may not produce useful 
results. 
6.3.4 Repeatability of Reactor Characterization Measurements 
The conversion and productivity values reported in Figure 5-10 were very 
promising, but they were only the result of a single batch of immobilized enzyme, packed 
into a single column, measured on a single day, with only a single trial for each flow rate. 
The validity of the experiment is not in question, but variability can happen in any system. 
Before a significant amount of time is spent developing a model to more accurately fit the 
results in Figure 5-10, the overall repeatability of the reaction system must be determined. 
If the error between reactor runs is greater than the uncertainty in the model, then time 
should be devoted to improving the experimental methods. Especially of interest is the 
repeatability of enzyme purification and immobilization from batch to batch, as well as the 
repeatability of column packing. The packing efficiency and any channelling effects or 
local disturbances due to bubbles or bead breakage has the potential to have a significant 
impact on reactor conversion. Thus, aliquots from the same batch of immobilized enzyme 
should be packed to the same bed height multiple times, and the relative conversion 
between the trials compared. Likewise, the repeatability of all other processes from enzyme 
expression to product quantification should be confirmed. 
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6.3.5 Empirical Approach to Reactor Characterization 
Rather than developing a theoretical model for reactor performance which is fit 
based on measured physical properties of the enzyme and substrates, it may be more 
effective to develop an empirical model for the reactor system instead. Once the 
repeatability of all the processes used to set up the flow reactor is established, a multi-
factorial design of experiments (DOE) approach could be used to design a set of 
experiments to optimize for conversion or productivity. Factors in the design might include 
enzyme loading, temperature, NAD+ concentration in the feed, flow rate, etc. The statistical 
theory behind DOE is well established and would provide a useful framework for future 
characterization of the reactor platform while minimizing the number of time-consuming 
experiments required. 
6.3.6 Scale-Up of Enzyme Production and Immobilization 
To carry out the experiments required for a theoretical or empirical model of the 
continuous packed bed reactor system, a large quantity of immobilized enzyme will be 
required. The Bommarius research group has a 10 L fed-batch fermenter which has the 
capability to produce much larger batches of enzyme at higher efficiency than fermentation 
in baffled shaking flasks with autoinduction media. The ability to produce an order of 
magnitude more enzyme than was possible in the reported work will change the types of 
experiments which can be run.  
Additionally, the experiments I conducted at Merck during an internship in 2019 
suggest that once immobilized onto the Nuvia IMAC resin, the biocatalysts could be easily 
lyophilized and would likely remain stable for months on the bench or longer in the freezer. 
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Immobilization of one large batch of enzymes which can be aliquoted for repeated 
experiments makes a big difference in the ease of future experiments and removes some of 
the potential repeatability issues related to variations between enzyme batches. An 
exploration of stabilization of immobilized AmDH and FDH for long-term storage should 
be explored, especially as the process moves from bench scale to a potential pilot scale.  
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